Attenuated Live Vaccines for Aquatic Animals

Safe and effective live vaccines against bacteria infecting aquatic animals were created through the induction of novobiocin-resistance in liquid culture and novobiocin- and rifampicin-resistance in liquid culture.

Skip to: Description  ·  Claims  · Patent History  ·  Patent History
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to novel microorganisms and vaccines for the protection of aquatic animals from bacterial diseases such as, motile Aeromonas septicemia, enteric septicemia, and streptococcal diseases. This invention also relates to methods for using the novel vaccines to protect aquatic animals from bacterial disease as well as to methods for preparing the vaccines using novel antibiotic resistance strategies.

2. Description of the Related Art

Disease problems constitute the largest single cause of economic losses in aquaculture and bacterial infections constitute the most important source of disease problems in various types of production (Meyer, 1991, J. Anim Sci. Volume 69, 4201-4208). Estimated economic impact from infections caused by bacterial infection on aquaculture industry annually is at least $10 million in the USA alone and more than $100 million globally (Shoemaker et al., 2010. J. Fish Dis. Volume 33, 537-44).

Antibiotics and chemotherapeutic drugs have been used for disease management in feed additives and in direct administration into fish pond water; however, there has been an increase in drug resistant strains (Son et al., 1997, Letters in Appl. Microbiol., Volume 24, 479-482); (Harikrishnan and Balasundaram, 2005, Reviews in Fisheries Science, Volume 13, 281-320).

Edwardsiella ictaluri (E. ictaluri) causes enteric septicemia of catfish (ESC) which is the most prevalent disease affecting farm-raised catfish, Ictalurus punctatus. E. ictaluri is a facultative Gram-negative flagellated bacterium akin to phylogenetically related Salmonella (Thune et al., J. World Aqua Soci, Volume 28, 193-201, 1997; Zhang and Arias, Syst. Appl. Microbial., Volume 30, 93-101, 2007). ESC is responsible for approximately $20 to $30 million in annual losses to catfish farmers in the southeastern United States (Plumb and Vinitnantharat, J. Fish. Dis., Volume 16, 65-71, 1993). ESC is generally an acute septicemia that develops very quickly, resulting in heavy mortalities at as early as 4 days after infection (Thune et al., supra; Newton et al., J. Fish. Dis., Volume 12, 335-347, 1989; Wolters and Johnson, J. Aquat. Anim Health, Volume 6, 329-334, 1994).

Streptococcus iniae is a significant fish pathogen impacting aquaculture production worldwide. Since its original isolation in 1976 from Amazon freshwater dolphin (Inia geoffrensiss) (Pier and Madin, 1976, Inyt. J. Syst. Bacteriol, Volume 26, 545-553), Streptococcus iniae has become a major aetiological agent of Streptococcus in farmed and wild finfish worldwide, affecting more than 30 species of fish, including trout, yellowtail, tilapia, barramundi, and hybrid striped bass (Cheng et al, 2010, Vaccine Volume 28, 2636-2641; Eyngor et al., 2008, Appl. Environ Microbiol., Volume 74, 6892-6897; Agnew and Barnes, 2007, Vet. Microbiol., Volume 122, 1-15; Ferguson et al., 2000, Vet Rec Volume 147, 662-664; Barnes, 2007, Vet Microbiol., Volume 122, 1-15; Ferguson et al., 2000, Vet Rec., Volume 147, 662-664; Bromage et al., 1999, Dis Aquat Organ, Volume 36, 177-181; Eldar et al., 1999, Dis Aquat Organ, Volume 36, 121-127). More recently, this bacterium has also been identified as a potential zoonotic pathogen, with at least 25 cases of human infection by S. iniae confirmed to date (Agnew and Barnes, 2007, supra; Sun et al., 2007, J. Med. Microbiol., Volume 56, 1246-1249; Koh et al., 2004, Emerg Infect Dis, Volume 10, 1694-1696; Weinstein et al., 1997, N. Engl J. Med., Volume 337, 589-594).

Edwardsiella tarda is a Gram-negative, motile, rod-shaped, aquatic bacterial pathogen which is highly infectious in both warm and cold water fish species. The bacterium is commonly encountered in channel catfish ponds, intensive tilapia culture, and eel production systems and is, therefore, a constant threat of disease. In the channel catfish (Ictalurus punctatus), E. tarda, the causative agent of enteric septicemia disease, has been isolated from channel catfish in areas of the southeastern United States. The disease also affects numerous other cultured fish species, sport fish, such as large-mouth bass, baitfish, and aquarium fishes. Wyatt et al. (Applied Environmental Microbiology, Volume 38, 710-714, 1979) found that in E. tarda positive catfish ponds, this bacterium was isolated from 75% of the pond water, 64% of pond mud, and 100% of apparently healthy frog, turtle, and crayfish samples. Meyer and Bullock (Applied Microbiology, Volume 25, 155-156, 1973) highlighted the food safety problem of E. tarda when they reported that 88% of dressed catfish were culture-positive for E. tarda. This usually results in a shut down of the processing lines until they are cleaned and disinfected because of the potential risk of human infection.

Streptococcus agalactiae is a Group B streptococcal bacterium that causes severe economic losses in a number of species of cultured and wild fish. This infectious bacterium is common in aquaculture facilities where fish are intensively cultured in fresh, brackish, or marine waters. The high densities of fish and the aqueous environment favor the rapid transmission of streptococcal disease. Moreover, infected cultured fish may transmit the disease to wild fish populations or infected wild fish may transmit the disease to cultured popultations.

Aeromonas hydrophila infection results in hemorrhagic septicemia and heavy mortalities in cultured and wild fish. There is no product that has been licensed for use against the motile aeromonads within the United States (Cipiano, R. C., 2001, Revision of Fish Disease Leaflet 68, U.S. Dept. Interior, Fish and Wildlife Service Div. of Fishery Res., Washington, D.C.).

Methods to control diseases in fish include the use of chemical therapeutics such as antibiotic-medicated food (Darwish 2007, Journal of Aquatic Animal Health, Volume 19, 1-7). However, large scale use of antibiotics in aquaculture is expensive and usually ineffective because sick fish normally do not eat. Furthermore, fish have developed resistance to approved food fish antibiotics, such as oxytetracycline, florfenical, and ormethorprimsulphamethoxine (Eldar et al., Dis. Aquat. Organ., Volume 36, 121-127, 1999; Sun et al, J. Med. Microbiol., Volume 56, 1246-1249, 2007; Tu et al., 2008, Microb Drug Resist. Volume 14, 311-316; Nawaz et al., 2006, Appl. Environ. Microbiol., Volume 72, 6461-6466; Balotescu et al., 2003, Roum. Arch. Microbiol. Volume 62, 179-189; Hatha et al., 2005, Int. J. Food Microbiol., Volume 98, 131-134; Saavedra et al., 2004, Int. Microbiol., Volume 7, 207-211.)

Alternative methods to control fish diseases include the use of vaccines. The most extensively studied Streptococcus iniae vaccines are killed bacterins consisting of formalin killed bacteria cells of pathogenic Streptococcus iniae strains (Eldar et al, 1997, Vet. Immunol. Immunopathol., Volume 56, 175-183; Bercovier et al., 1997, Dev. Biol. Stand., Volume 90, 153-160). These formalin killed bacteria cells of Streptococcus iniae have been previously successfully used as vaccines to protect rainbow trout in Israel. However, recently, it has been reported that these killed vaccines are unable to protect fish from infection by other isolates (serotypes) of Streptococcus iniae (Bachrach et al, 2001, Appl Environ Microbiol, Volume 67, 3756-3758; Eyngor et al., 2008, Appl Environ Microbiol, Volume 74, 6892-6897). In addition to killed vaccines, live attenuated S. iniae strains defective in phosphglucomutase and M-like protein have been reported to offer protection against homologous S. iniae challenge (Locke et al., PLoS One, Volume 3, c2824, 2008; Buchanan et al., Infect. Immun., Volume 73, 6935-6944, 2005). However, it is not clear whether they offer protection against heterologous S. iniae.

Attenuated live bacterial vaccines such as rifampicin-resistant Edwardsiella ictaluri (AquaVac-ESC) and Flavobacterium columnare (AquaVac-COL), both licensed to Intervet/Shering-Plough, have been developed through a rifampicin-resistant strategy (Klesius and Shoemaker, 1999, Adv. Vet. Med., Volume 41, 523-537; Shoemaker et al., 2007, Vaccine, Volume 25, 1126-1131) and offer great protection against infections by E. ictaluri and F. columnare. Rifampicin works by inhibiting DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA and subsequent translation to proteins (Schullz and Zillig, 1981, Nucleic Acids Res., Volume 9, 689-6906). This strategy relies on the ability of rifampicin to induce the appearance of rough mutants on relatively solid culture media, i.e., agar plates. It has been demonstrated that the rifampicin-resistant RE-33 strain of E. ictaluri was unable to cause ESC, but was able to stimulate protective immunity in catfish (Klesius and Shoemaker, Adv. Vet. Med., Volume 41, 523-537, 1999). However, it is not clear whether other antibiotics could also be used to attenuate bacteria for the purpose of novel vaccine development.

Klesius et al. (US Patent Application Publication 2010/0221286, Sep. 2, 2010) discloses a modified live rifampicin-resistant Aeromonas hydrophila vaccine for aquatic animals wherein the Aeromonas hydrophila mutants were modified by using a low initial concentration of 2.5 μg/ml rifampicin and ending at about 320 μg/ml of rifampicin after 44 passages of bacteria on relatively solid culture media, i.e., agar plates. The mutants obtained by this method were used to vaccinate fish either by intraperitoneal (IP) injection or bath immersion.

Klesius et al. (U.S. Pat. No. 6,019,981, Feb. 1, 2000 and U.S. Pat. No. 6,153,202, Nov. 28, 2000) disclose modified live rifampicin-resistant Edwardsiella ictaluri vaccines for aquatic animals wherein the E. ictaluri mutants were modified by using a low initial concentration of 5.0 μg/ml rifampicin and ending at about 320 μg/ml of rifampicin after 44 passages of bacteria on relatively solid culture media, i.e., agar plates. The mutants obtained by this method were used to vaccinate fish both post-hatch and in ovo using bath immersion.

Evans et al. (U.S. Pat. No. 7,067,122) disclose a rifampicin-resistant live vaccine against Edwardsiella tarda. E. tarda was grown on modified tryptic soy agar (TSA) plates in increasing concentrations of rifampicin starting at 10 μg/ml and ending at 320 mg/ml, increasing at 20 μg/ml increments.

Evans et al. (U.S. Pat. No. 7,204,993, Apr. 17, 2007) disclose a Streptococcus agalactiae vaccine prepared with killed cells of isolated β-hemolytic Streptococcus agalactiae.

Novobiocin, also known as albamycin or cathomycin, is a natural antibiotic produced by the actinomycete Streptomyces niveus, a member of the order of Actinobacteria (Kominek, 1972, Antimicrob. Agents Chemother., Volume 1, 123-134). Novobiocin works as a natural inhibitor of bacterial DNA gyrase, resulting in bacterial cell-death (Gellert et al., 1976, Proc. Natl. Acad. Sci. USA, Volume 73, 4474-4478). DNA gyrase, an ATP-dependent enzyme that acts by creating a transient double-stranded DNA break, is essential for efficient DNA replication, transcription, and recombination by catalyzing the negative supercoiling of DNA (Mdluli and Ma, 2007, Infec. Disord. Drug Targets, Volume 7, 159-168).

While various vaccines have been developed that are effective for Aeromonas hydrophila, Edwardsiella ictaluri, Edwardsiella tarda, Streptococcus agalactiae and Streptococcus iniae infections of aquatic animals, there remains a need in the art for efficacious and safe vaccines for the aquaculture industry. The present invention described below includes attenuated live vaccines and provides methods for treating aquatic animals using said vaccines as well as methods for preparing live attenuated bacterial vaccines that are efficacious and safe and different from related art vaccines and methods.

SUMMARY OF THE INVENTION

It is therefore an object of the present invention to provide live attenuated bacterial vaccines.

Another object of the present invention is to provide live attenuated bacterial vaccines for aquatic animals.

Another object of the present invention is to provide live attenuated Edwardsiella ictaluri vaccines for aquatic animals.

A still further object of the present invention is to provide live novobiocin-resistant attenuated Edwardsiella ictaluri vaccines for aquatic animals.

Another object of the present invention is to provide a live attenuated novobiocin-resistant attenuated Edwardsiella ictaluri vaccine wherein said vaccine contains the strain of E. ictaluri NRRL B-50348.

Another object of the present invention is to provide live attenuated Edwardsiella tarda vaccines for aquatic animals.

A still further object of the present invention is to provide live coumermycin-resistant attenuated Edwardsiella tarda vaccines for aquatic animals.

Another object of the present invention is to provide live coumermycin-resistant attenuated Edwardsiella tarda vaccines wherein said vaccines contain Edwardsiella tarda strain NRRL B-50467 and/or NRRL B-50468.

Another object of the present invention is to provide live attenuated Streptococcus iniae vaccines for aquatic animals.

A still further object of the present invention is to provide a live novobiocin-resistant attenuated Streptococcus iniae vaccine for aquatic animals.

Another object of the present invention is to provide live novobiocin-resistant attenuated Streptococcus iniae vaccine wherein said vaccine contains the strain S. iniae NRRLB-50368.

Another object of the present invention is to provide live attenuated Streptococcus agalactiae vaccines for aquatic animals.

A still further object of the present invention is to provide a live coumermycin-resistant attenuated Streptococcus agalactiae vaccine for aquatic animals.

Another object of the present invention is to provide live coumermycin-resistant attenuated Streptococcus agalactiae vaccine wherein said vaccine contains the strain S. agalactiae NRRL B-50460.

A still further object of the present invention is to provide live attenuated Aeromonas hydrophila vaccines for aquatic animals wherein said Aeromonas hydrophila vaccines comprise Aeromonas hydrophila selected from the deposited strains NRRL B-50369, B-50418, B-50419 and mixtures thereof.

Another object of the present invention is to provide a method for preventing and/or reducing enteric septicemia in aquatic animals by administering at least one live attenuated Edwardsiella vaccine.

A further object of the present invention is to provide a method for preventing and/or reducing enteric septicemia in aquatic animals by administering at least one live attenuated Edwardsiella vaccine wherein said vaccine contains a strain of Edwardsiella selected from the group consisting of NRRL B-50348, B-50467, B-50468, and mixtures thereof.

Another object of the present invention is to provide a method for preventing and/or reducing streptococcal disease in aquatic animals by administering live attenuated Streptococcus vaccine.

A further object of the present invention is to provide a method for preventing and/or reducing streptococcal disease in aquatic animals by administering a live attenuated Streptococcus vaccine wherein said vaccine contains a strain of Streptococcus selected from the group consisting of NRRL B-50368, B-50460, and mixtures thereof.

Another object of the present invention is to provide a method for preventing and/or reducing motile Aeromonas septicemia in aquatic animals by administering a live attenuated Aeromonas hydrophila vaccine.

A further object of the present invention is to provide a method for preventing and/or reducing motile Aeromonas septicemia in aquatic animals by administering a live attenuated Aeromonas hydrophila vaccine wherein said vaccine contains a strain of A. hydrophila selected from the group consisting of NRRL 13-50369, B-50418, 13-50419 and mixtures thereof.

Another object of the present invention is to provide a method for preparing attenuated live bacterial vaccines using a novobiocin-resistance strategy to develop novel attenuated bacteria for use as safe, efficacious vaccines.

Another object of the present invention is to provide a method for preparing attenuated live bacterial vaccines using a strategy that includes both rifampicin-resistance and novobiocin-resistance to develop novel attenuated bacteria for use as safe, efficacious vaccines.

Further objects and advantages of the present invention will become apparent from the following description.

Deposit of the Microorganisms

Aeromonas hydrophila strains NRRL B-50369, NRRL B-50418, and NRRL B-50419 were deposited on May 7, 2010, Sep. 29, 2010, and Sep. 29, 2010 respectively. Edwardsiella ictaluri strain NRRL B-50348 was deposited on Feb. 25, 2010. Streptococcus iniae strain NRRL B-50368 was deposited on May 7, 2010. Edwardsiella tarda strains NRRL B-50467 and NRRL B-50468 were deposited on Feb. 4, 2011. Streptococcus agalactiae strain NRRL B-50460 was deposited Jan. 18, 2011. They were deposited under the provisions of the Budapest Treaty, on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and the Regulations there under (Budapest Treaty) with the U.S.D.A. Agricultural Research Service Patent Culture Collection, National Center for Agricultural Utilization Research, 1815 N. University Street, Peoria, Ill. 61604. Access to this deposit will be available during the pendency of the application to the Commissioner of Patents and Trademarks and persons determined by the Commissioner to be entitled thereto upon request under 37 C.F.R. 1.14 and 35 U.S.C. 122. The deposits are available as required by foreign patent laws in countries where counterparts of the subject application, or it progeny are filed. However, it is to be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by a government action. Upon allowance of any claims in the application, the Applicant(s) will maintain and will make this deposit available to the public pursuant to the Budapest Treaty.

Further, the subject isolate deposits will be stored and made available to the public in accord with the provisions of the Budapest Treaty for the Deposit of Microorganisms, i.e., they will be stored with all the care necessary to keep them viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposit, and in any case, for a period of at least 30 (thirty) years after the date of deposit or for the enforceable life of any patent which may issue disclosing the isolates. The depositor acknowledges the duty to replace the deposits should the depository be unable to furnish a sample when requested, due to the condition of the deposits. All restrictions on the availability to the public of the subject isolate deposits will be irrevocably removed upon the granting of a patent disclosing it.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a photograph showing growth of AL93-58, RE-33, and B-50348 on 5% sheep blood agar plates. The three strains were streaked out onto 5% sheep blood agar plates and incubated at approximately 27 degrees C. for about 48 hours.

FIG. 2 is a graph showing daily mean percent cumulative mortality of intraperitoneal injected vaccinated channel catfish challenged by virulent AL93-58 strain of Edwardsiella ictaluri through intraperitoneal injection. Daily mean percent cumulative mortalities were calculated from three trials. Data are represented as mean±S.D. from the three trials.

FIG. 3 is a graph showing daily mean percent cumulative mortality of immersion vaccinated channel catfish challenged by virulent AL93-58 strain of Edwardsiella ictaluri through intraperitoneal injection. Daily mean percent cumulative mortalities were calculated from two trials. Data are represented as mean±S.D. from the two trials.

FIGS. 4A and 4B are photographs showing the growth of Streptococcus iniae ISET0901 and Streptococcus iniae ISNO on 5% sheep blood agar plates. The two strains were streaked out onto 5% sheep blood agar plates and incubated at 27° C. for approximately 24 h (FIG. 4A) or approximately 96 h (FIG. 4B). The dark area around the bacteria colony on 5% sheep blood agar plates represents hemolytic activity.

FIG. 5 is a graph showing daily mean percent cumulative mortality of Nile tilapia vaccinated through intraperitoneal injection with or without Streptococcus iniae ISNO and challenged with homologous virulent Streptococcus iniae ISET0901 strain through intraperitoneal injection. Daily mean percent cumulative mortalities were calculated from all vaccine trials at 14, 28, 60, 90, and 180 days post vaccination. Data are represented as mean±S.D. from all five trials.

FIG. 6 is a graph showing daily mean percent cumulative mortality of Nile tilapia vaccinated through intraperitoneal injection with or without Streptococcus iniae ISNO and challenged with heterologous virulent strains of Streptococcus iniae through intraperitoneal injection. Daily mean percent cumulative mortalities were calculated from five heterologous Streptococcus iniae isolates (F3CB, 102F1K, 405F1K, 1F6, and ARS60) challenges at 60 days post vaccination. Data are represented as mean±S.D. from the five trials.

FIG. 7 is a graph showing antibody titres of pre-challenged fish vaccinated with or without Streptococcus iniae ISNO. Data are represented as mean±S.D. from three replicates.

FIG. 8 is a photograph showing growth of parent Streptococcus agalactiae Sag3P and coumermycin-resistant Streptococcus agalactiae Sag3C on 5% sheep blood agar plates. The two strains were streaked out onto 5% sheep blood agar plates and incubated at 27° C. for 24 h.

FIG. 9 is a graph showing daily mean percent cumulative mortality of Nile tilapia vaccinated with Streptococcus agalactiae Sag3C through intraperitoneal injection and challenged by virulent parent strain of Streptococcus iniae Sag3P through intraperitoneal injection. Daily mean percent cumulative mortalities were calculated from three vaccination trials (i.e., 14, 21, and 60 days post vaccination). Data are represented as mean±S.D. from the three trials.

FIG. 10 is a graph showing the growth of the coumermycin-resistant Edwardsiella tarda Eta9C, the virulent parent E. tarda Eta9P, the coumermycin-resistant E. tarda Eta 11C, and the virulent parent E. tarda Eta11P on 5% sheep blood agar plates. Similar amount of the parent and mutant strains were plated out onto the 5% sheep blood agar plates and incubated at 27° C. for 24 h.

FIG. 11 is a photograph showing growth of Aeromonas hydrophila AL09-72 (AL #1) and Aeromonas hydrophila N+R−1 on 5% sheep blood agar plates. The two strains were streaked out onto 5% sheep blood agar plates and incubated at 27° C. for 24 h. Picture shown is a representative of four replicates of growth experiment on 5% sheep blood agar plates.

FIGS. 12A and 12B are photographs showing growth of Aeromonas hydrophila AL09-71 (AL#4) and Aeromonas hydrophila N+R−4 on tryptic soy agar plates. The two strains were either streaked out onto 5% sheep blood agar plates (FIG. 12A) or plated onto tryptic soy agar plates by spreading 100 ul overnight culture onto the surface of the plate (FIG. 12B) and incubated at 27° C. for approximately 24 h.

FIGS. 13A and 13B are photographs showing growth of Aeromonas hydrophila AL09-73 (AL #2) and Aeromonas hydrophila N+R−2 on tryptic soy agar plates. The two strains were either streaked out onto 5% sheep blood agar plates (FIG. 13A) or plated out onto tryptic soy agar plates by spreading 100 ul overnight culture onto the surface of the plate (FIG. 13B) and incubated at 27° C. for approximately 24 h.

FIG. 14 is a graph showing daily mean percent cumulative mortality of Aeromonas hydrophila N+R−1 vaccinated channel catfish through intraperitoneal injection followed by challenge with virulent Aeromonas hydrophila AL09-72 (AL41) through intraperitoneal injection. Daily mean percent cumulative mortalities were calculated from four vaccination doses/trials of approximately 5×104, 1×105, 2×105, and 4×105 CFU/fish. Data are represented as mean±S.D. from the four trials.

FIG. 15 is a graph showing the daily mean percent cumulative mortality of Aeromonas hydrophila N+R−1 vaccinated Nile tilapia through intraperitoneal injection followed by challenge with virulent Aeromonas hydrophila AL09-72 (AL#1) through intraperitoneal injection. Daily mean percent cumulative mortalities were calculated from two vaccination doses/trials (1.4×107 and 1.4×108 CFU/fish). Data are represented as mean±S.D. from the two trials.

FIG. 16 is a graph showing the daily mean percent cumulative mortality of Aeromonas hydrophila N+R−4 intraperitoneally injection vaccinated channel catfish challenged by virulent Aeromonas hydrophila AL09-71 (AL#4) through intraperitoneal injection. Daily mean percent cumulative mortalities were calculated from four vaccination doses/trials (4.75×104, 9.5×104, 1.9×105, and 3.8×105 CFU/fish). Data are represented as mean±S.D. from the four trials.

FIG. 17 is a graph showing the daily mean percent cumulative mortality of Aeromonas hydrophila N+R−4 intraperitoneally injection vaccinated Nile tilapia challenged by virulent Aeromonas hydrophila AL09-71 (AL#4) through intraperitoneal injection. Daily mean percent cumulative mortalities were calculated from three vaccination doses/trials (1.3×106, 1.3×107, and 1.3×108 CFU/fish). Data are represented as mean±S.D. from the three trials.

FIG. 18 is a graph showing daily mean percent cumulative mortality of Aeromonas hydrophila N+R−2 intraperitoneally injection vaccinated channel catfish challenged by virulent Aeromonas hydrophila AL09-73 (AL#2) through intraperitoneal injection. Daily mean percent cumulative mortalities were calculated from four vaccination doses/trials (3.13×104, 6.25×104, 1.25×105, and 2.50×105 CFU/fish). Data are represented as mean±S.D. from the four trials.

FIG. 19 is a graph showing the daily mean percent cumulative mortality of Aeromonas hydrophila N+R−2 intraperitoneally injection vaccinated Nile tilapia challenged by virulent Aeromonas hydrophila AL0973 (AL#2) through intraperitoneal injection. Daily mean percent cumulative mortalities were calculated from three vaccination doses/trials (1.2×106, 1.2×107, and 1.2×108 CFU/fish). Data are represented as mean±S.D. from the three trials.

The present invention provides novel, live vaccines and methods for making and using said vaccines using any bacterium that produces a disease state in animals. More particularly, the present invention provides novel effective live vaccines and methods for making and using such vaccines for controlling diseases in aquatic animals, including, but not limited to, Aeromonas hydrophila, Edwardsiella ictaluri, Edwardsiella tarda, Streptococcus agalactiae and Streptococcus iniae.

DETAILED DESCRIPTION OF THE INVENTION

The vaccines disclosed in the present invention are also effective in controlling diseases caused by Aeromonas hydrophila, Edwardsiella ictaluri, Edwardsiella tarda, Streptococcus agalactiae, and Streptococcus iniae in a variety of fish when administered thereto. Without being limited thereto, the vaccine is especially beneficial for the treatment of tilapia (Oreochromis sp.), channel catfish (I. punctutus), American, European, and Japanese eels (Anguilla sp.), salmonids (Oncorhynchus sp. and Salmo sp.), striped bass and hybrid-striped bass (Morone chrysops×M. saxatilis), flounders (Seriola sp.), seabream (Sparus sp.), sea perch (Lates calcarifer), the estuarine grouper (Ephinephelus tawine), walleye (Zander vitreum), centrachids (such as large mouth bass, Micropterus samoides), bullheads (Nebulosus sp.), bait minnows (Pimephales promelas), golden shiners (Netemigonus crysoleucas), goldfish (Carassius auratus), carp (Cyprinus carpio) and aquarium fish species such as black mollies (Poecilia sphenops) and platies (Xiphosphorus maculates). The use of these attenuated live Aeromonas hydrophila, Edwardsiella ictaluri, Edwardsiella tarda, Streptococcus agalactiae, and Streptococcus iniae vaccines offer several benefits that include reducing disease loss in fresh and marine water fish and eel production, diminishing the food safety risks to humans, and reducing the contamination of water by A. hydrophila, Edwardsiella ictaluri, Edwardsiella tarda, Streptococcus agalactiae, and Streptococcus iniae that may be discharged in the environment from fish production systems.

Unless otherwise specified, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

Vaccine is defined herein in its broad sense to refer to any type of biological agent in an administrable form capable of stimulating a protective immune response in an animal inoculated with the vaccine.

Effective immunization or vaccination dose or dosage is defined herein as being the amount that will induce complete or partial immunity in a vaccinated aquatic animal against a subsequent challenge by a virulent strain.

Relative percent survival (RPS) is a measure of protection following experimental challenge as described by Amend (Dev. Bio. Stand., Volume 49, 447-454, 1981; which is herein incorporated by reference in its entirety). RPS is calculated according to the formula: RPS=(1−vaccinate mortality÷control mortality)×100. A positive vaccine effect is indicated by a RPS equal or greater than about 60%.

Efficacious vaccine is defined herein as a vaccine that offers equal or greater than about 60% protection against pathogen infections.

Rifampicin, also known as rifampin, is a bactericidal antibiotic drug of the rifamycin group. It is a semisynthetic compound derived from Amycolatopsis rifamycinica (formerly known as Amycolatopsis mediterranei and Streptomyces mediterranie).

Rifampicin-resistant strategy is defined as a strategy that uses rifampicin to induce rifampicin resistance in bacteria. Rifampicin works by inhibiting DNA-dependent RNA polymerase in bacterial cells by binding it beta-subunit, thus preventing transcription to RNA and subsequent translation to proteins.

Novobiocin, also known as albamycin or cathomycin, is an aminocoumarin antibiotic that is produced by the actinomycete Streptomyces niveus, which has recently been identified as a subjective synonym for Streptomyces spheroids, a member of the order Actinobacteria. Novobiocin also includes novobiocin-like chemicals including for example, coumermycin.

Novobiocin-resistance strategy is defined as a strategy that uses novobiocin or a novobiocin-like chemical, such as coumermycin, to induce novobiocin resistance in bacteria. Novobiocin and novobiocin-like chemicals are natural inhibitors of bacterial DNA gyrase.

Attenuation is defined as the gradual loss of virulence of a pathogen.

Novobiocin-resistant strains of bacteria, such as, for example, Edwardsiella ictaluri, and Streptococcus iniae, were created by multiple passages of isolates of virulent strains of the bacteria of interest. Serial passage of these isolates over increasing concentrations of novobiocin produces strains with an attenuated pathogenicity efficacious for the preparation of live vaccines. The attenuation achieved by the high-level serial passage in liquid culture on increasing concentrations of novobiocin virtually eliminates the pathogenicity of the bacterium toward aquatic animals. The starting concentration for novobiocin that allowed overnight growth was approximately 12.5 μg/ml for Edwardsiella ictaluri, and approximately 1 ng/ml for Streptococcus iniae. The starting concentration for novobiocin-like coumermycin that allowed overnight growth was approximately 312.5 ng/ml for Edwardsiella tarda, and approximately 1 ng/ml for Streptococcus agalactiae.

A method for making live attenuated bacterial vaccines uses novobiocin or any chemical that functions the same as novobiocin, i.e. any DNA gyrase inhibitor also referred to as a novobiocin-like compound, such as, for example, coumermycin. Serial passages of bacteria isolates in increasing amounts of novobiocin in liquid culture produce novobiocin-resistant bacterial mutants. Determining the starting concentration of novobiocin or a novobiocin-like compound is microorganism dependent and determination of the concentration is well within the ordinary skill in the art given the detailed description and examples of the present specification. The bacteria are attenuated by serial passage in any suitable growth media, including, but not limited to, liquid media, solid media, or partial soft and partial liquid media. For example, Edwardsiella ictaluri and Streptococcus iniae were attenuated by serial passage in tryptic soy broth (TSB) containing increasing concentrations of novobiocin. Streptococcus agalactiae and Edwardsiella tarda were attenuated by serial passage in tryptic soy broth (TSB) containing increasing concentrations of coumermycin.

The E. ictaluri strains were passaged approximately 12 times using increasing concentrations of novobiocin. Initially E. ictaluri was able to grow overnight in brain heart infusion broth containing 12.5 μg/ml of novobiocin. Approximately 10 μl of that overnight culture was added into approximately 1 ml of tbrain heart infusion broth containing 25 μg/ml of novobiocin. If the cells were able to grow in brain heart infusion broth containing 25 μg/ml of novobiocin, approximately 10 μl of the overnight culture containing novobiocin at concentration of 25 μg/ml was then added into approximately 1 ml of brain heart infusion broth containing 50 μg/ml of novobiocin. However, if the cells from the overnight culture at concentration of 12.5 μg/ml of novobiocin were unable to grow in brain heart infusion broth containing 25 μg/ml of novobiocin, then approximately 10 μl of the overnight culture containing novobiocin at concentration of 12.5 μg/ml was added into approximately 1 ml of brain heart infusion broth containing novobiocin equal to or higher than 12.5 μg/ml but less than 25 μg/ml. This process was repeated multiple times until the cells were able to grow in culture media containing novobiocin at concentration of approximately 800 μg/ml.

The S. iniae strains were passed approximately 20 times using increasing concentrations of novobiocin, starting with a concentration of approximately 1 ng/ml which allowed overnight growth of S. iniae. Approximately 10 μl of that overnight culture was added into approximately 1 ml of tryptic soy broth containing 2 ng/ml of novobiocin. If the cells were able to grow in tryptic soy broth containing 2 ng/ml of novobiocin, approximately 10 μl of the overnight culture containing novobiocin at concentration of 2 ng/ml was then added into approximately 1 ml of tryptic soy broth containing 4 ng/ml of novobiocin. However, if the cells from the overnight culture at concentration of 1 ng/ml of novobiocin were unable to grow in tryptic soy broth containing 2 ng/ml of novobiocin, then approximately 10 μl of the overnight culture containing novobiocin at concentration of 1 ng/ml was added into approximately 1 ml of tryptic soy broth containing novobiocin equal to or higher than 1 ng/ml but less than 2 ng/ml. This process was repeated again and again until the cells were able to grow in culture media containing novobiocin at concentration of approximately 1000 ng/ml.

The Streptococcus agalactiae strains were passed approximately 20 times using increasing concentrations of coumermycin, a novobiocin-like antibiotic, starting with a concentration of approximately 1 ng/ml which allowed overnight growth of S. agalactiae. Approximately 10 μl of that overnight culture was added into approximately 1 ml of tryptic soy broth containing 2 ng/ml of coumermycin. If the cells were able to grow in tryptic soy broth containing 2 ng/ml of coumermycin, approximately 10 μl of the overnight culture containing coumermycin at concentration of 2 ng/ml was then added into approximately 1 ml of tryptic soy broth containing 4 ng/ml of coumermycin. However, if the cells from the overnight culture at concentration of 1 ng/ml of coumermycin were unable to grow in tryptic soy broth containing 2 ng/ml of coumermycin, then approximately 10 μl of the overnight culture containing coumermycin at concentration of 1 ng/ml was added into approximately 1 ml of tryptic soy broth containing coumermycin equal to or higher than 1 ng/ml but less than 2 ng/ml. This process was repeated again and again until the cells were able to grow in culture media containing coumermycin at concentration of approximately 5000 ng/ml.

The Edwardsiella tarda strains were passaged approximately 20 times using increasing concentrations of coumermycin, a novobiocin-like antibiotic, starting with a concentration of approximately 312.5 ng/ml which allowed overnight growth of E. tarda. Approximately 10 μl of that overnight culture was added into approximately 1 ml of tryptic soy broth containing 625 ng/ml of coumermycin. If the cells were able to grow in tryptic soy broth containing 625 ng/ml of coumermycin, approximately 10 μl of the overnight culture containing coumermycin at concentration of 625 ng/ml was then added into approximately 1 ml of tryptic soy broth containing 1250 ng/ml of coumermycin. However, if the cells from the overnight culture at concentration of 312.5 ng/ml of coumermycin were unable to grow in tryptic soy broth containing 625 ng/ml of coumermycin, then approximately 10 μl of the overnight culture containing coumermycin at concentration of 1 ng/ml was added into approximately 1 ml of tryptic soy broth containing coumermycin equal to or higher than 312.5 ng/ml but less than 625 ng/ml. This process was repeated again and again until the cells were able to grow in culture media containing coumermycin at concentration of approximately 640 μg/ml.

Another method to make antibiotic resistant attenuated vaccine strains includes using both rifampicin- and novobiocin-resistance strategy. Strains of bacteria such as, for example, Aeromonas hydrophila, were created by multiple passages of isolates of virulent strains of the bacteria of interest. Serial passage of these isolates over increasing concentrations of rifampicin and novobiocin produces strains with an attenuated pathogenicity efficacious for the preparation of live vaccines. The attenuation was achieved by serial passages in culture media containing increasing concentrations of novobiocin and rifampicin. The starting concentration of novobiocin and rifampicin that allowed overnight growth of Aeromonas hydrophila was approximately 10 μg/ml. Approximately 10 μl of that overnight culture was then added into approximately 1 ml of tryptic soy broth containing 20 μg/ml of novobiocin and 20 μg/ml of rifampicin. If the cells were able to grow in tryptic soy broth containing 20 μg/ml of novobiocin and rifampicin, approximately 10 μl of the overnight culture containing novobiocin and rifampicin at concentration of 20 μg/ml was then added into approximately 1 ml of tryptic soy broth containing 40 μg/ml of novobiocin and 40 μg/ml of rifampicin. However, if the cells from the overnight culture containing 10 μg/ml of novobiocin and 10 μg/ml of rifampicin were unable to grow in tryptic soy broth containing 20 μg/ml of novobiocin and 20 μg/ml of rifampicin, then approximately 10 μl of the overnight culture containing 10 μg/ml of novobiocin and 10 μg/ml of rifampicin was added into approximately 1 ml of tryptic soy broth containing novobiocin and rifampicin equal to or higher than 10 μg/ml but less than 20 μg/ml. This process was repeated multiple times until the cells were able to grow in culture media containing approximately 1600 μg/ml of novobiocin and 1600 μg/ml of rifampicin.

The native strain of Aeromonas hydrophila should be passaged a sufficient number of times such that in its new attenuated form it no longer possesses the ability of causing the disease state known as motile Aeromonas septicemia in tilapia, channel catfish, and other fish. The methodology for attenuation by serial passage is well know and documented in the art as exemplified by Schurig et al., (Vet. Micro. Volume 28, 171-188, 1991), herein incorporated by reference, who used rifampicin-resistant strategy and created modified live rifampicin-resistant Brucella vaccines.

Vaccination can be accomplishable by injection, oral ingestion, or by means of aqueous immersion. The bacterial agent is prepared for administration by formulation in an effective immunization dosage with an acceptable carrier or diluent, such as for example, water. Effective immunization dosage and immunologically effective amount or dosage are defined herein as being that amount which will induce complete or partial immunity or elicit a protective immune response in a treated fish against subsequent challenge by a virulent strain of a bacteria. Immunity is considered as having been induced in a population as evidenced by a decrease in the number of infected aquatic animals or a decrease in the severity of infection and is significantly higher than that of an unvaccinated control group measured at a confidence level of at least about 80% preferably measured at a confidence level of at least about 95%. The appropriate effective dosage can be readily determined by the practioner skilled in the art especially in light of the teachings of the present specification. One measure of protection following experimental challenge is relative percent survival (RPS) as described by Amend (Dev. Bio. Stand., Volume 49, 447-454, 1981) herein incorporated by reference. RPS is calculated according to the formula:

RPS = 1 - % vaccinate mortality % control mortality × 100

A positive vaccine effect is indicated by a RPS equal to or greater than about 60%. Typically, the vaccine is administered to an aquatic animal by bath immersion, intraperitoneal or intramuscular injection, and/or any oral delivery or immersion device. Aquatic animals are vaccinated by immersion in water containing approximately 1×102 to approximately 1×109 CFU/ml of immersion medium. Useable vaccination times are seen to range from about 1 minute to 120 minutes, depending on the penetration of the pathogen and the formulation of the vaccine. Temperature of the inoculation media may range within the physiologically acceptable limits of the aquatic animal involved, for tilapia and channel catfish preferably from about 18 degrees C. to about 32 degrees C., most preferably from about 20 degrees C. to about 30 degrees C. Concentrations of fish treated in the inoculation medium typically range from about 50 to about 100 fish/L, but, in the alternative may be determined on a weight basis and range from about 0.5 to about 2.5 kg/L. For intraperitoneal injection (IP injection), fish may be vaccinated within a range of about 1×102 CFU/fish to about 1×109 CFU/fish. The vaccine can be effectively administered any time after the fish attains immunocompetence, which for tilapia is at about two to fourteen days post-hatch and for channel catfish, after about 7-10 days post-hatch. Other species of fish can be immunized after about 21-30 days post-hatch or when they become immunocompetent to modified live vaccine administered by immersion.

To produce large amounts of the vaccine strains of bacteria for the preparation of vaccines, the bacterium may be cultivated under any conventional conditions and on media which promote growth of the bacterium.

Without being limited thereto, attenuated live Edwardsiella ictaluri, Streptococcus iniae, Streptococcus agalactiae, Edwardsiella tarda and Aeromonas hydrophila strains, for vaccine production, may be grown on a variety of liquid media types, including but not limited to, tryptic soy broth, brain heart infusion broth, and Lysogeny broth medium. The cultures are typically incubated at approximately 25-30 degrees C. for a period of time sufficient to produce maximum levels of cells, generally about 24 to 48 hours. Alternatively, the strains may be grown on a variety of sold media, including, but not limited to, Lysogeny broth agar, Helellea agar or tryptic soy agar (TSA). Without being limited thereto, conventional tryptic soy broth (TSB) is preferred. The production of the vaccine in this manner may be conducted by stationary culture of the strains at about 25-30 degrees C. for about 5 to about 7 days. All-vegetable based fermentation media are also preferred for use herein, as the use thereof eliminates the risks of the presence of animal products and infectious agents in the final vaccine product.

Live cells of the strains are prepared for administration to aquatic animals, especially fish, by formulation in an immunologically effective amount or dosage. The dose may further include pharmaceutically acceptable carriers and adjuvants know in the art.

As noted above, the cells may be formulated in an optional, pharmaceutically acceptable carrier such as water, physiological saline, mineral oil, vegetable oils, aqueous sodium carboxymethyl cellulose, or aqueous polyvinylpyrrolidone. The vaccine formulations may also contain optional adjuvants, antibacterial agents, or other pharmaceutically active agents as are conventional in the art. Without being limited thereto, suitable adjuvants include but are not limited to mineral oil, vegetable oils, alum, and Freund's incomplete adjuvant. Still other preferred adjuvants include microparticles or beads of biocompatible matrix materials. The microparticles may be composed of any biocompatible matrix as are conventional in the art, including but not limited to agar and polyacrylate. The practitioner skilled in the art will recognize that other carriers or adjuvants may be used as well. For example, other adjuvants which may be used are described by Webb and Winkelstein (In: Basic & Clinical Immunology, 1984, Stites et al, (Eds), Fifth edition, Lange Medical Publications, Los Altos, Calif., Pages 282-285, 1984), the contents of which are herein incorporated by reference.

The vaccines of the present invention may be administered to the subject animal by any convenient route which enables the cells to elicit an immune response, such as by IP or intramuscular injection, bath immersion, oral administration, or nasal administration. However, IP injection or bath immersion is preferred for primary immunization, while oral immunization is preferred for secondary or booster immunization, when necessary. It is also envisioned that the surface of the fish may be punctured such as described by Nakanishi et al. (Vaccine, Volume 20, 3764-3769, 2002) or otherwise abraded or slightly descaled, prior to or during bath immersion, to facilitate exposure of the vaccine to the animal's immune system. The vaccine may be administered in a single dose or in a plurality of doses. Dependent upon rearing conditions, the vaccine may be administered in multiple doses, the timing of which may be readily determined by the skilled artisan.

Vaccination against bacterial infection by bath immersion immunization offers several advantages over other routes of immunization. Among these advantages are lower cost per fish immunized, mass immunization of large numbers of fish, reduced stress, significantly higher rates of fish survival and the absence of adverse reactions to vaccination. Furthermore, bath immersion vaccination is an effective method for mass vaccination of smaller fish that cannot be injected or subjected to skin punctures. Alternatively, IP injection of commercially available fish vaccines is commonly employed on fresh or marine aquaculture farms due to their reliability and high efficacy despite high cost per fish immunized and stress to the fish.

The following examples are intended only to further illustrate the invention and are not intended to limit the scope of the invention as defined by the claims.

Example 1

A virulent strain of Edwardsiella ictaluri, strain AL93-58, was used for induction of novobiocin resistance. The strain was isolated in 1993 from diseased catfish in Alabama and is stored at the Aquatic Animal Health Research Unit, Auburn, Ala. Initial cultures of the AL93-58 strain were grown in brain heart infusion broth containing no antibiotics at approximately 27 degrees C. for about 24 hours. The virulent strain of AL93-58 was then subjected to selection for resistance to novobiocin By culturing the bacterium in brain heart infusion broth (BHI) (Fisher Scientific, Pittsburgh, Pa.) containing different concentrations of novobiocin as detailed in Table 1. The initial concentration of novobiocin that allowed growth of AL93-58 was approximately 12.5 μg/ml. After 12 passages of AL93-58 in BHI culture media containing higher doses of novobiocin, the novel novobiocin-resistant strain of AL93-58 Novo-800 (NRRL B-50348) was able to grow in BHI broth containing approximately 800 μg/ml of novobiocin.

Table 1 shows the novobiocin concentration and passage number used in the induction of novobiocin-resistant E. ictaluri. The starting concentration that allowed growth of AL93-58 was approximately 12.5 μg/ml. After 12 passages, the novel strain B-50348 of AL93-58 was able to grow in BHI containing approximately 800 μg/ml of novobiocin whereas the parent strain AL93-58 failed to grow in BHI containing 25 μg/ml or higher.

TABLE 1 Concentrations and passages used in the induction of novobiocin-resistant E. ictaluri strain from strain AL-93-58. Novobiocin Conc Date Passage No. μg/ml Growth Jun. 10, 2009 1 0 Yes Jun. 10, 2009 1 12.5 Yes Jun. 10, 2009 1 25 No Jun. 11, 2009 2 0 Yes Jun. 11, 2009 2 12.5 Yes Jun. 11, 2009 2 25 No Jun. 12, 2009 3 0 Yes Jun. 12, 2009 3 12.5 Yes Jun. 12, 2009 3 25 No Jun. 15, 2009 4 0 Yes Jun. 15, 2009 4 12.5 Yes Jun. 15, 2009 4 15 Yes Jun. 15, 2009 4 20 Yes Jun. 16, 2009 5 0 Yes Jun. 16, 2009 5 20 Yes Jun. 16, 2009 5 25 Yes Jun. 16, 2009 5 30 Yes Jun. 16, 2009 5 50 Yes Jun. 16, 2009 5 75 Yes Jun. 16, 2009 5 100 Yes Jun. 17, 2009 6 0 Yes Jun. 17, 2009 6 100 Yes Jun. 17, 2009 6 150 Yes Jun. 17, 2009 6 200 Yes Jun. 18, 2009 7 0 Yes Jun. 18, 2009 7 200 Yes Jun. 18, 2009 7 250 Yes Jun. 18, 2009 7 300 Yes Jun. 19, 2009 8 0 Yes Jun. 19, 2009 8 300 Yes Jun. 19, 2009 8 350 No Jun. 19, 2009 8 400 No Jun. 20, 2009 9 0 Yes Jun. 20, 2009 9 300 Yes Jun. 20, 2009 9 350 Yes Jun. 20, 2009 9 400 Yes Jun. 23, 2009 10 0 Yes Jun. 23, 2009 10 400 Yes Jun. 23, 2009 10 450 Yes Jun. 23, 2009 10 500 Yes Jun. 24, 2009 11 0 Yes Jun. 24, 2009 11 500 Yes Jun. 24, 2009 11 550 Yes Jun. 24, 2009 11 600 Yes Jun. 25, 2009 12 0 Yes Jun. 25, 2009 12 600 Yes Jun. 25, 2009 12 650 Yes Jun. 25, 2009 12 700 Yes Jun. 25, 2009 12 750 Yes Jun. 25, 2009 12 800 Yes

Example 2

The growth and biochemical characteristics of Edwardsiella ictaluri Novo-800 were determined and compared to other strains of E. ictaluri. When Edwardsiella ictaluri AL93-58, Edwardsiella ictaluri Novo-800, and a rifampicin resistant Edwardsiella ictaluri RE-33 as described by Klesius and Shoemaker (1999, Adv. Vet. Med., Volume 41, 523-537) were plated on 5% sheep blood agar plates, the growth of Edwardsiella ictaluri AL93-58 were the fastest, followed by Edwardsiella ictaluri RE-33. However, the growth of Edwardsiella ictaluri Novo-800 was the slowest (FIG. 1).

Biochemical analysis using API-20E bacterial identification test strip (Biomérieux, Durham, N.C.) revealed that Edwardsiella ictaluri AL93-58, Edwardsiella ictaluri Novo-800, and Edwardsiella ictaluri RE-33 were identical (Table 2).

TABLE 2 Results of the API-20E bacterial identification test strip for Edwardsiella ictaluri AL93-58, Edwardsiella ictaluri Novo-800, and Edwardsiella ictaluri RE-33 Results (positive or negative) AL93- Novo- Tests Reactions/Enzymes 58 800 RE-33 ONPG β-galactosidase negative negative negative ADH Arginine dihydrolase negative negative negative LDC Lysine decarboxylase positive positive positive ODC Ornithine decarboxylase negative negative negative CIT Citrate utilization negative negative negative H2S H2S production negative negative negative URE Urease negative negative negative TDA Tryptophane deaminase positive positive positive IND Indole production negative negative negative VP Acetoin production positive positive positive GEL Gelatinase negative negative negative GLU Fermentation/oxidation(glucose) positive positive positive MAN Fermentation/oxidation(mannitol) negative negative negative INO Fermentation/oxidation(inositol) negative negative negative SOR Fermentation/oxidation(sorbitol) negative negative negative RHA Fermentation/oxidation(rhamnose) negative negative negative SAC Fermentation/oxidation(saccharose) negative negative negative MEL Fermentation/oxidation(melibiose) negative negative negative AMY Fermentation/oxidation(amygdalin) negative negative negative ARA Fermentation/oxidation(arabinose) negative negative negative OX Cytochrome-oxidase negative negative negative

Example 3

To study the safety of Edwardsiella ictaluri strain Novo-800 (NRRL B-50348) compared to E. ictaluri AL93-58 and E. ictaluri RE-33, the three strains of E. ictaluri were cultured overnight in brain heart infusion broth at approximately 27 degrees C. A total of 1120 channel catfish (Ictalurus punctatus) were exposed to the three strains of E. ictaluri by bath immersion. All channel catfish (Industry pool strain, USDA, ARS, Catfish Genetics Research Unit, Stoneville, Miss.) used in this study were raised at the USDA ARS Aquatic Animal Health Research facility located at Auburn, Ala. and naïve to E. ictaluri. Bath immersion was performed by immersing catfish in water containing different concentrations (colony forming unit/CFU; Table 3) of Edwardsiella ictaluri for one hour. Mortalities were recorded for 14 days post exposure to E. ictaluri.

TABLE 3 Safety of Edwardsiella ictaluri AL93-58, RE-33, and Novo-800 to catfish by bath immersion Strain used Fish in bath weight Exposure Dose. Mortality immersion (g) No. of fish method (CFU/ml) (%) BHI control 0.38 20 immersion — 0 AL93-58 0.38 20 immersion 2.5 × 105 0 Novo-800 0.38 20 immersion 2.6 × 105 0 RE-33 0.38 20 immersion 2.4 × 105 0 BHI control 0.85 20 immersion — 0 AL93-58 0.85 20 immersion 4.8 × 105 0 Novo-800 0.85 20 immersion 5.3 × 105 0 RE-33 0.85 20 immersion 5.2 × 105 0 BHI control 0.85 20 immersion — 0 AL93-58 0.85 20 immersion 2.4 × 106 10 Novo-800 0.85 20 immersion 2.7 × 106 0 RE-33 0.85 20 immersion 2.6 × 106 0 acumulative mortality was calculated at 14 days post treatment days post exposure bBrain heart infusion culture media

Example 4

The safety of Edwardsiella ictaluri Novo-800 to catfish by intraperitoneal injection was compared to Edwardsiella ictaluri RE-33 and Edwardsiella ictaluri AL93-58. All three strains of Edwardsiella ictaluri were cultured overnight in brain heart infusion (BHI) broth at 27° C. All catfish (Industry pool strain, USDA, ARS, Catfish Genetics Research Unit, Stoneville, Miss.) used in this study were raised at the USDA ARS Aquatic Animal Health Research facility located at Auburn, Ala. and naïve to Edwardsiella ictaluri. Different concentrations (colony forming unit/CFU) of Edwardsiella ictaluri were injected to catfish intraperitoneally. Mortalities were recorded for 14 days post exposure to E. ictaluri.

When 11 g fish were injected with approximately 2.4×106 CFU of Edwardsiella ictaluri AL93-58, all fish died (Table 4). When same size fish were injected approximately 2.2×106 CFU of Edwardsiella ictaluri RE-33, mortality was about 75%. However, when same size fish were injected approximately 2.8×106 CFU of Edwardsiella ictaluri Novo-800, no fish died (Table 4).

When 14 g fish were intraperitoneally injected with approximately 2.5×106 CFU of Edwardsiella ictaluri AL93-58, about 95% fish died (Table 4). When same size fish were intraperitoneally injected with approximately 2.4×106 CFU of Edwardsiella ictaluri RE-33, mortality was about 65%. However, when same size fish were intraperitoneally injected with approximately 2.8×106 CFU or approximately 4.2×106 CFU of Edwardsiella ictaluri Novo-800, no fish died (Table 4).

TABLE 4 Safety of Edwardsiella ictaluri AL93-58, RE-33, and Novo-800 to catfish by intraperitoneal injection Strain used Fish weight No. of Exposure Mortality in injection (g) fish method Dosea (%)b BHIc control 11 20 injection — 0 AL93-58 11 20 injection 2.4 × 106 100 AL93-58 11 20 injection 1.6 × 106 95 AL93-58 11 20 injection 1.2 × 106 80 AL93-58 11 20 injection 9.6 × 105 70 RE-33 11 20 injection 2.2 × 106 75 RE-33 11 20 injection 1.5 × 106 60 RE-33 11 20 injection 1.1 × 106 45 RE-33 11 20 injection 8.9 × 105 35 Novo-800 11 20 injection 2.8 × 106 0 Novo-800 11 20 injection 1.8 × 106 0 Novo-800 11 20 injection 1.4 × 106 0 Novo-800 11 20 injection 1.1 × 106 0 BHI control 14 40 injection — 0 AL93-58 14 40 injection 2.5 × 106 95 AL93-58 14 40 injection 1.7 × 106 93 AL93-58 14 40 injection 1.3 × 106 93 AL93-58 14 40 injection 1.0 × 106 88 RE-33 14 40 injection 3.6 × 106 83 RE-33 14 40 injection 2.4 × 106 65 RE-33 14 40 injection 1.8 × 106 30 RE-33 14 40 injection 1.4 × 106 33 Novo-800 14 40 injection 4.2 × 106 0 Novo-800 14 40 injection 2.8 × 106 0 Novo-800 14 40 injection 2.1 × 106 0 Novo-800 14 40 injection 1.7 × 106 0 adose by injection is in the unit of CFU per fish; vaccination concentration by IM is in the unit of CFU per milliliter bcumulative mortality was calculated at 14 days post treatment days post exposure cbrain heart infusion culture media

Example 5

Channel catfish, ranging in size from approximately 8 to 14 grams and age from approximately 3 months to 9 months, were used to test a vaccine containing Edwardsiella ictaluri strain Novo-800 (NRRL B-50348). Novo-800 was cultured in BHI broth at approximately 27 degrees C. at approximately 125 rpm overnight before vaccination. Catfish were vaccinated by IP injection. For sham-vaccination controls, channel catfish were IP injected with BHI. After one and two months post vaccination, channel catfish were challenged by virulent Edwardsiella ictaluri strain AL 93-58 strain of E. ictaluri through IP injection using a dose of approximately 1.8×105 CFU per fish which was the LD50 value of AL93-58 by IP injection. Mortalities were recorded for approximately 14 days post challenge and the presence or absence of E. icatluri in dead fish were determined as described above. Results of experimental challenge were presented as relative percent survival (RPS) as described previously (Klesius et al., 2000, supra). RPS was calculated according to the following formula:


RPS={1−vaccinated mortality/control mortality)}×100.

At 22 days post vaccination, when Edwardsiella ictaluri Novo-800 vaccinated catfish were challenged by virulent Edwardsiella ictaluri AL93-58, only 5% fish died (Table 5). However, 70% fish died in the BHI sham vaccinated control. The RPS of Edwardsiella ictaluri Novo-800 vaccinated fish at 22 dpv was 93% (Table 5). At 32 days post vaccination, when Novo-800 vaccinated catfish were challenged by virulent Edwardsiella ictaluri AL93-58, only 5% fish died. However, 60% fish died in the BHI sham vaccinated control. The RPS of Edwardsiella ictaluri Novo-800 vaccinated fish at 32 dpv was 92% (Table 5). At 63 days post vaccination, when Edwardsiella ictaluri Novo-800 vaccinated catfish were challenged by virulent Edwardsiella ictaluri AL93-58, no fish died. However, 75% fish died in the BHI sham vaccinated control. The RPS of Edwardsiella ictaluri Novo-800 vaccinated fish at 63 dpv was 100% (Table 5). When catfish were challenged by virulent Edwardsiella ictaluri AL93-58, cumulative mortalities of Edwardsiella ictaluri Novo-800 vaccinated fish at different time points (different days post vaccination) were significantly (P<0.05) lower than that of BHI sham-vaccinated fish (FIG. 2).

TABLE 5 Cumulative mortality and relative percent survival (RPS) of intraperitoneal injection vaccinated catfish challenged with Edwardsiella ictaluri AL93-58 virulent strain Fish Vaccination starting Challenge Mortal- Vaccine dose weight Dose ity RPSb group (CFU/fish) (g) (CFU/fish) dpva (%) (%) BHIc control — 11 1.7 × 105 22 70 — B-50348 1.84 × 106 11 1.7 × 105 22 5 93 B-50348 1.38 × 106 11 1.7 × 105 22 5 93 BHI control — 8 2.0 × 105 32 60 — B-50348 8.67 × 106 8 2.0 × 105 32 5 92 BHI control — 8 2.2 × 105 63 75 — B-50348 8.67 × 106 8 2.2 × 105 63 0 100  adays post vaccination; brelative percent survival; cbrain heart infusion broth

Example 6

The efficacy of Edwardsiella ictaluri Novo-800 through bath immersion vaccination was tested on channel catfish. Channel catfish used in this experiment were approximately 8 grams and approximately 3 months old. Edwardsiella ictaluri Novo-800 was cultured in BHI broth at approximately 27° C. at about 125 rpm overnight before vaccination. Catfish were bath immersed in water containing approximately 2.7×107 CFU/ml of Edwardsiella ictaluri Novo-800 for about 1 h. As sham-vaccination controls, channel catfish were bath immersed in water containing same amount of BHI used for Edwardsiella ictaluri Novo-800 vaccine (sham vaccination). After about 37 and about 57 days post vaccination, channel catfish were challenged by virulent Edwardsiella ictaluri AL93-58 through intraperitoneal injection. Mortalities were recorded for about 14 days post challenge. Results of experimental challenge were presented as RPS.

When Edwardsiella ictaluri Novo-800 vaccinated catfish were challenged by virulent Edwardsiella ictaluri AL93-58, no fish died at about 37 days post vaccination. However, approximately 30% of the fish died in the BHI sham vaccinated control. The relative percent survival of Edwardsiella ictaluri Novo-800 vaccinated fish at about 37 dpv was 100% (Table 6).

At 57 days post vaccination, when Edwardsiella ictaluri Novo-800 vaccinated catfish were challenged by virulent Edwardsiella ictaluri AL93-58, no fish died. However, 40% fish died in the BHI sham vaccinated control. The RPS of Edwardsiella ictaluri Novo-800 vaccinated fish at 57 dpv was 100% (Table 6).

When catfish were challenged by virulent Edwardsiella ictaluri AL93-58, cumulative mortalities of Edwardsiella ictaluri Novo-800 vaccinated fish at different time points (different days post vaccination) were significantly (P<0.05) lower than that of BHI sham-vaccinated fish (FIG. 3).

TABLE 6 Cumulative mortality and relative percent survival (RPS) of vaccinated catfish challenged by virulent Edwardsiella ictaluri AL93-58 Fish Challenge Mortal- Vaccine starting Dose No. fish ity RPSb group weight (g) (CFU/fish) challenged dpva (%) (%) BHIc control 8 1.2 × 105 20 37 30 — Novo-800 8 1.2 × 105 20 37 0 100 BHI control 8 2.2 × 105 20 57 40 — Novo-800 8 2.2 × 105 20 57 0 100 avaccination concentration by immersion is in the unit of CFU per milliliter brelative percent survival cbrain heart infusion culture media

Example 7

Eight Streptococcus iniae isolates obtained from different fish species exhibiting clinical streptococcal disease and from different geographical regions (Table 7) were used for the induction of novobiocin resistance. The archived isolates were recovered from frozen stocks (approximately 2 nil aliquots stored at approximately −80 degrees C.) and grown in tryptic soy broth (TSB) (Fisher Scientific, Pittsburgh, Pa.) for approximately 24 hours at approximately 28 degrees C. All strains were cultured in tryptic soy broth containing different concentrations of novobiocin sodium salt (Promega, Madison, Wis.) for approximately 24 to 48 hours at approximately 28 degrees C. The initial concentration of novobiocin that allowed overnight growth of Streptococcus iniae was approximately 1 ng/ml. Approximately 10 μl of that overnight culture was added into approximately 1 ml of tryptic soy broth containing 2 ng/ml of novobiocin. If the cells were able to grow in tryptic soy broth containing 2 ng/ml of novobiocin, approximately 10 μl of the overnight culture containing novobiocin at concentration of 2 ng/ml was then added into approximately 1 ml of tryptic soy broth containing 4 ng/ml of novobiocin. However, if the cells from the overnight culture at concentration of 1 ng/ml of novobiocin were unable to grow in tryptic soy broth containing 2 ng/ml of novobiocin, then approximately 10 μl of the overnight culture containing novobiocin at concentration of 1 ng/ml was added into approximately 1 ml of tryptic soy broth containing novobiocin equal to or higher than 1 ng/ml but less than 2 ng/ml. This process was repeated again and again until the cells were able to grow in culture media containing novobiocin at concentration of approximately 1000 ng/ml. After about 20 passages of Streptococcus iniae in TSB culture media containing the same or higher concentrations of novobiocin, all eight Streptococcus iniae strains were able to grow in TSB containing approximately 1 μg/ml of novobiocin.

TABLE 7 Streptococcus iniae isolates used in this study Isolate designation Location Species of fish IF6-F3 Minnesota, USA Oreochromis niloticus × O. aureus ISET0901 Israel Oreochromis niloticus Kent-02 California, USA Morone saxatilis × M. chrysops Uruguay 1.1/28 Uruguay Acipenser gueldenstaedtii 15-Br Minnesota, USA Oreochromis niloticus Uruguay 1 Uruguay Acipenser gueldenstaedtii Kent 08 California, USA Morone saxatilis × M. chrysops 35-Br Idaho, USA Oreochromis spp.

The eight parent and novobiocin-resistant Streptococcus iniae strains were then grown on approximately 5% sheep blood agar plates (Thermo Fisher Scientific Remel Products, Lenexa, Kans.) for bacterial identification. Bacteria isolates were identified by API 20 Strep test (BioMerieux, Durham, N.C.) and gas chromatography analysis of fatty acid methyl ester using MIDI microbial identification system (MIDI, Newark, Del.), according to established procedures (Shoemaker et al, 2005, J. Aqua Animal Health Volume 17, 267-274).

Biochemical analysis using API-20 strep identification test revealed that all isolates shared similar biochemical profiles to know S. iniae deposited in the Mini API strip reading system (BioMerieux, Durham, N.C.), which were positive for β-glucosidase, arginine dihydrolase, ribodse acidification, L-arabinose acidification, mannitol acidification, trehalose acidification, starch acidification, and glycogen acidification, but negative for all others. Gas chromatograph analysis of fatty acid methyl ester using MIDI microbial identification system also confirmed that parent and novobiocin-resistant mutants were Streptococcus iniae. When parent Streptococcus iniae ISET0901 isolate and novobiocin-resistant S. iniae ISNO were plated onto 5% sheep blood agar plates, parent isolate grew much faster than the novobiocin-resistant ISNO isolate, as shown in FIGS. 5A and 5B. Parent S. iniae ISET0901 isolate also showed hemolytic activity, whereas ISNO failed to show hemolytic activity (FIGS. 4A and 4B).

Example 8

To study the virulence of novobiocin-resistant S. iniae isolates compared to their parent isolates, all bacteria were cultured overnight in TSB at approximately 28 degrees C. An optical density (OD) of 1.0 of the bacterial cultures was measured at about 540 nm using Thermospectronic spectrophotomer (Fisher Scientific, Pittsburgh, Pa.). Serial dilutions (in triplicates) of each isolate were prepared in TSB and approximately 100 μl of serially diluted S. iniae were plated onto TSA plates. After about 24 hours incubation at approximately 28 degrees C., the average number of CFU/ml was calculated for all isolates. Similar amount of each parent and novobiocin-resistant isolate was exposed to Nile tilapia, having a mean weight of approximately 10.4±0.6 grams, through intraperitoneal (IP) injection. Three concentrations (CFU/ml) for each isolate were injected into Nile tilapia using ten fish per concentration. All fish used were male tilapia raised at the USDA ARS Aquatic Animal Health Research facility located at Auburn, Ala. Fish were acclimated in flow-through 57-L aquaria supplied with approximately 0.5 L h−1 dechlorinated water for about 10 days prior to experiments. A 12:12 hour light:dark period was maintained and supplemental aeration was supplied by an air stone. Fish were fed approximately 3% body weight daily with commercial dry fish food. During the experiment, the mean dissolved oxygen was approximately 5.6 mg L−1, temperature was approximately 26 degrees C., pH was approximately 7.1, and hardness was approximately 100 mg L−1. Mortalities were recorded for approximately 14 days post exposure to S. iniae.

Virulence data of both novobiocin-resistant and susceptible parent isolates of S. iniae are shown in Table 8. When novobiocin-resistant S. iniae isolates were IP injected into Nile tilapia, four out of eight isolates (ISET0901-N, Kent02-N, Uruguay 1-N, and 35Br-N) caused no mortality or less than 10% mortality at all three injection doses. However, when injected at a high dose of 2×107 CFU per fish, their respective parent isolates caused 100, 50, 40 and 30% mortality, respectively (Table 8). The most virulent parent Streptococcus iniae isolates were Streptococcus iniae IF6-F3 and Streptococcus iniae ISET0901, both of which killed 100% of Nile tilapia at a dose of approximately 2×107 CFU per fish (Table 8).

TABLE 8 Virulence of novobiocin-resistant (N) and parent isolates (P) of S. iniae to Nile tilapia by intraperitoneal injection Mortality at Mortality at 2 × 107 dose 1 × 107 dose Mortality at 1 × 106 dose Isolate name (%) b(%) (%) IF6-F3-Na 70 70 0 IF6-F3-Pb 100 80 40 ISET0901-N 0 0 0 ISET0901-P 100 100 100 Kent02-N 0 10 0 Kent02-P 50 10 0 Uruguay1.1-N 10 10 10 Uruguay1.1-P 10 0 0 15Br-N 50 50 40 15Br-P 50 50 50 Uruguay 1-N 10 0 0 Uruguay 1-P 40 0 0 Kent08-N 20 0 0 Kent08-P 20 0 0 35Br-N 0 0 0 35Br-P 30 10 0 aN stands for novobiocin-resistant isolate; bP stands for parent isolate.

Example 9

Nile tilapia were vaccinated with novobiocin-resistant Streptococcus iniae isolates and then challenged with parent isolates to test for protection against Streptococcus iniae. Attenuated novobiocin-resistant S. iniae vaccines were cultured in TSB at approximately 28 degrees C. at approximately 125 rpm overnight before vaccination. Fish were vaccinated by IP injection. Initial screen for the most safe and effective S. iniae vaccine were performed by using three vaccination doses in a total volume of approximately 100 μl for each vaccine and ten fish per dose. As sham vaccination controls, approximately 100 μl of TSB were injected into each fish, 10 fish total.

At approximately thirty days post vaccination (dpv), fish were challenged by the parent isolate of S. iniae through IP injection. Mortalities were recorded for approximately 14 days post challenge. Results of S. iniae challenge are presented as relative percent survival (RPS) and RPS was calculated as described above in example 5. The four novobiocin-resistant S. iniae isolates that killed less than about 10% tilapia when injected at high dose were then subjected to initial vaccine screen. When novobiocin-resistant ISET0901 (ISET0901-Novo, called ISNO, NRRL B-50368) vaccinated fish were challenged by its virulent parent isolate at 28 dpv, relative percent survival of vaccinated fish was 100% (Table 9). However, when novobiocin-resistant Uruguay 1 vaccinated fish were challenged by its virulent parent isolate, RPS value at 28 dvp was only about 33% (Table 8). Novobiocin-resistant 35Br and Kent02 failed to protect fish at 28 dpv, with RPS value of zero (Table 9).

TABLE 9 Cumulative mortality and relative percent survival (RPS) of vaccinated tilapia challenged with virulent parent isolates Vaccination Isolate Challenge dose used for Dose Mortality RPSe Vaccine group (CFU/fish) challenge (CFU/fish) d.p.v.a (%) (%) Sham TSB — ISET0901-Pd 1.0 × 105 28 90 — ISET0901-Nc 1.0 × 107 ISET0901-P 1.0 × 105 28 0 100  Sham TSB — Uruguay1-P 2.6 × 108 28 30 — Uruguay1-N 1.3 × 108 Uruguay1-P 2.6 × 108 28 20 33  Sham TSB — 35Br—P 4.2 × 107 28 20 — 35Br—N 2.1 × 107 35Br—P 4.2 × 107 28 30 0 Sham TSB — Kent02-P 1.7 × 108 28 50 — Kent02-N 8.5 × 107 Kent02-P 1.7 × 108 28 50 0 adays post vaccination; bintraperitoneal injection; cnovobiocin-resistant isolate; dvirulent parent isolate; e relative percent survival

Example 10

To determine the effective immunization dose of Streptococcus iniae ISNO in Nile tilapia by intraperitoneal injection vaccination, six doses of approximately 1×102, 1×103, 1×104, 1×105, 1×106, and 1×107 CFU/fish in a total volume of approximately 100 μl were intraperitoneally injected into Nile tilapia using 30 fish per dose. As sham-vaccination control, fish were injected in the same manner with TSB. All bacteria were cultured in TSB broth at approximately 28 degrees centigrade at about 125 rpm overnight before vaccination or challenge. At 28 days post vaccination, vaccinated fish were challenged by virulent parent strain S. iniae ISET0901 and the challenge dose was approximately 1.5×107 CFU per fish by injection.

To determine the effective immunization dose of Streptococcus iniae ISNO by immersion, concentrations of approximately 1×105, 1×106, and 1×107 CFU/ml in total volume of approximately 5 L were used. A total of 30 Nile tilapia per concentration were immersed for 4 hours in the presence of approximately 0.02% Tween-20. As sham-vaccination control, fish were bath immersed in TSB containing approximately 0.02% Tween-20.

Results of minimum vaccination dose of ISNO to protect tilapia from infection by virulent S. iniae ISET0901 are summarized in Table 10. When IP vaccinated fish were challenged by ISET0901 isolate at about 28 days post vaccination, RPS values were all 100% when vaccination dose was approximately 1×104 CPU/fish or higher (Table 10). When Nile tilapia were vaccinated at dose of approximately 1×103CFU/fish by IP, RPS value of vaccinate fish was approximately 95%. Relative percent survival of IP vaccinated fish at the lowest vaccination dose of approximately 1×102 CFU/fish was approximately 86% (Table 10 and FIG. 6). When Nile tilapia was vaccinated by ISNO through bath immersion, RPS of vaccinated fish at about 28 days post vaccination was approximately 88% with the highest vaccination dose of approximately 1×107 CFU/ml. When the vaccination dose was reduced to approximately 1×106 CFU/ml, RSP value for vaccinated fish dropped to approximately 63% (Table 10) and when vaccination dose was decreased to approximately 1×105 CFU/ml, RPS value for vaccinated fish at about 28 days post vaccination was only approximately 13% (Table 10).

TABLE 10 Minimum effective vaccination dose of ISNO to protect tilapia from infection by virulent S. iniae ISET0901 Vacci- Challenge Mortal- Vaccine nation Vaccination Dose ity RPSe group route dosea (CFU/fish) d.p.v.b (%) (%) Sham TSB IPc — 1.0 × 105 28 84 — ISNO IP 1.0 × 107 1.0 × 105 28 0 100 ISNO IP 1.0 × 106 1.0 × 105 28 0 100 ISNO IP 1.0 × 105 1.0 × 105 28 0 100 ISNO IP 1.0 × 104 1.0 × 105 28 0 100 ISNO IP 1.0 × 103 1.0 × 105 28 4 95 ISNO IP 1.0 × 102 1.0 × 105 28 12 86 Sham TSB IMd — 1.0 × 105 28 64 — ISNO IM 1.0 × 107 1.0 × 105 28 8 88 ISNO IM 1.0 × 106 1.0 × 105 28 24 63 ISNO IM 1.0 × 105 1.0 × 105 28 56 13 avaccination dose for IP and IM was in the unit of CFU/fish and CFU/ml, respectively bdays post vaccination cintraperitoneal injection dbath immersion erelative percent survival

Example 11

The attenuated S. iniae (ISNO) obtained from ISET0901 isolate that showed best protection in the initial vaccine trial was then subjected to backpassage safety studies. One hundred and eighty fish were divided into two groups, control group and vaccine group, with 90 fish per group. The 90 fish were then divided into 6 fish tanks with 15 fish per tank.

Approximately one hundred microliters (μl) of S. iniae ISNO overnight bacterial culture containing approximately 1.0 to 1.5×107 CFU were IP injected into each tilapia. This dose was approximately 1000 times of the effective immunization dose (approximately 1.0×104 CFU of Streptococcus iniae ISNO). Control group fish were injected with TSB. About forty-eight hours later, five fish were taken from the first tank and homogenized. Approximately 100 μl of the homogenate was injected into each fish in Tank 2. The homogenate was also cultured on a blood agar plate to determine the presence or absence of S. iniae. This backpassage procedure was repeated five times using the rest of the fish. Mortality or adverse behavior or signs of disease were recorded for about 21 days post injection.

Of all fish exposed to S. iniae ISNO vaccine through IP injection, no mortality or signs of disease or adverse behavior was observed. No fish died in the back passage studies either after exposure to S. iniae ISNO. No S. iniae was isolated from fish exposed to S. iniae ISNO by IP in the first IP or the following backpassage through injection of homogenates.

Example 12

To test the efficacy of Streptococcus iniae ISNO against homologous Streptococcus iniae challenge, both Streptococcus iniae ISET0901 and Streptococcus iniae ISNO were cultured in TSB at about 28° C. at about 125 rpm overnight before vaccination or challenge. Vaccination of Streptococcus iniae ISNO was performed at vaccination dose of approximately 1.0×107 CFU in a total volume of approximately 0.1 ml per fish through intraperitoneal injection. Sham vaccination was performed by injecting approximately 0.1 ml of tryptic soy broth to each fish. At about 14, 28, 60, 90, and 180 dpv, ten fish from each vaccination group (sham- or Streptococcus iniae ISNO-vaccinated) at each time point were challenged by its parent isolate Streptococcus iniae ISET0901 (homologous isolate) at dose of approximately 1.0×105 CFU per fish through intraperitoneal injection. Mortalities were recorded for about 14 days post challenge. Results of Streptococcus iniae challenge were presented as RPS.

At about 14 dpv, when TSB sham-vaccinated fish were challenged by virulent strain Streptococcus iniae ISET0901, approximately 90% fish died (Table 11). However, when Streptococcus iniae ISNO vaccinated fish were challenged by its homologous virulent strain Streptococcus iniae ISET0901, no fish died (Table 11). The RPS of Streptococcus iniae ISNO-vaccinated fish at about 14 dpv was 100% (Table 11). At about 28 dpv, when TSB sham-vaccinated fish were challenged by virulent strain Streptococcus iniae ISET0901, approximately 90% of the fish died (Table 11). However, when Streptococcus iniae ISNO vaccinated fish were challenged by its homologous virulent strain Streptococcus iniae ISET0901, no fish died (Table 11). The RPS of vaccinated fish at about 28 dpv was 100% (Table 11). At about 60 dpv, when TSB sham-vaccinated fish were challenged by virulent strain Streptococcus iniae ISET0901, approximately 90% of the fish died (Table 11). However, when Streptococcus iniae ISNO vaccinated fish were challenged by its homologous virulent strain Streptococcus iniae ISET0901, no fish died (Table 11). The RPS of vaccinated fish at about 60 dpv was 100% (Table 11). At about 90 dpv, when TSB sham-vaccinated fish were challenged by virulent strain Streptococcus iniae ISET0901, approximately 90% of the fish died (Table 11). However, when Streptococcus iniae ISNO vaccinated fish were challenged by its homologous virulent strain Streptococcus iniae ISET0901, only 10% fish died (Table 11). The RPS of vaccinated fish at about 90 dpv was approximately 89% (Table 11). At about 180 dpv, when TSB sham-vaccinated fish were challenged by virulent strain Streptococcus iniae ISET0901, approximately 90% of the fish died (Table 11). However, when Streptococcus iniae ISNO vaccinated fish were challenged by its homologous virulent strain Streptococcus iniae ISET0901, approximately 20% of the fish died (Table 11). The RPS of vaccinated fish at about 180 dpv was approximately 75% (Table 11). When fish were challenged by homologous Streptococcus iniae ISET0901, cumulative mortalities of Streptococcus iniae ISNO vaccinated fish at different time points were significantly (P<0.05) lower that of TSB sham-vaccinated fish (FIG. 5).

TABLE 11 Cumulative mortality and relative percent survival (RPS) of vaccinated Nile tilapia challenged with Streptococcus iniae ISET0901 Vaccination Challenge dose Dose Mortality RPSc Vaccine group (CFU/fish) (CFU/fish) dpva (%) (%) Sham TSB — 1.0 × 105 14 90 — ISNO 1.0 × 107 1.0 × 105 14 0 100 Sham TSB — 1.0 × 105 28 90 — ISNO 1.0 × 107 1.0 × 105 28 0 100 Sham TSB — 1.0 × 105 60 90 — ISNO 1.0 × 107 1.0 × 105 60 0 100 Sham TSB — 1.0 × 105 90 90 — ISNO 1.0 × 107 1.0 × 105 90 10  89 Sham TSB — 1.0 × 105 180 80 — ISNO 1.0 × 107 1.0 × 105 180 20  75 adays post vaccination; bintraperitoneal injection; crelative percent survival

Example 13

To test the efficacy of Streptococcus iniae ISNO against heterologous Streptococcus iniae challenge, Streptococcus iniae bacteria were cultured in TSB at Approximately 28° C. at about 125 rpm overnight before vaccination or challenge. Vaccination of Streptococcus iniae ISNO was performed at vaccination dose of approximately 1.0×107 CFU per fish through intraperitoneal injection. Cross protection against heterologous Streptococcus iniae isolates were performed at about 60 days post vaccination. For cross protection experiments, five virulent heterologous isolates (Table 12) were used.

TABLE 12 Streptococcus iniae isolates used in the heterologous challenge study Year Isolate designation isolated Location Species of fish ARS-60 2004 California, USA Morone saxatilis x M. chrysops IF6-F3 2008 Minnesota, USA Oreochromis niloticus M10032405#F1K 2010 Maine, USA Lates calcarifer M10021102#F1K 2010 Maine, USA Lates calcarifer M10021101#F3CB 2010 Maine, USA Lates calcarifer

Mortalities were recorded for about 14 days post challenge and the presence or absence of Streptococcus iniae in dead fish was determined as described earlier. Results of Streptococcus iniae challenge were presented as RPS. At approximately 60 dpv, when TSB sham-vaccinated fish were challenged by heterologous strain Streptococcus iniae ARS-98-60, approximately 80% fish died (Table 13). However, when Streptococcus iniae ISNO vaccinated fish were challenged by ARS-98-60, no fish died (Table 13). The relative percent survival of Streptococcus iniae ISNO-vaccinated fish against Streptococcus iniae ARS-98-60 challenge at about 60 dpv was 100%. At about 60 dpv, when TSB sham-vaccinated fish were challenged by heterologous strain Streptococcus iniae IF6-F3, 100% fish died (Table 13). However, when Streptococcus iniae ISNO vaccinated fish were challenged by Streptococcus iniae IF6-F3, no fish died (Table 13). The RPS of Streptococcus iniae ISNO-vaccinated fish against Streptococcus iniae IF6-F3 challenge at about 60 dpv was 100%. At about 60 dpv, when TSB sham-vaccinated fish were challenged by heterologous strain Streptococcus iniae 21101F3CB, approximately 90% fish died (Table 13). However, when Streptococcus iniae ISNO vaccinated fish were challenged by Streptococcus iniae 21101F3CB, approximately 20% fish died (Table 13). The RPS of Streptococcus iniae ISNO-vaccinated fish against Streptococcus iniae 21101F3CB challenge at about 60 dpv was 100%. At about 60 dpv, when TSB sham-vaccinated fish were challenged by heterologous strain Streptococcus iniae 21102F1K, 100% fish died (Table 13). However, when Streptococcus iniae ISNO vaccinated fish were challenged by Streptococcus iniae 21102F1K, approximately 10% fish died (Table 13). The RPS of Streptococcus iniae ISNO-vaccinated fish against Streptococcus iniae 21102F1K challenge at about 60 dpv was approximately 90%. At about 60 dpv, when TSB sham-vaccinated fish were challenged by heterologous strain Streptococcus iniae 32405F1K, 100% fish died (Table 13). However, when Streptococcus iniae ISNO vaccinated fish were challenged by Streptococcus iniae 32405F1K, no fish died (Table 13). The RPS of Streptococcus iniae ISNO-vac at about 60 dpv, when Streptococcus iniae ISNO- or TSB sham-vaccinated fish were challenged by heterologous strains of Streptococcus iniae, cumulative mortalities of Streptococcus iniae ISNO-vaccinated fish were significantly (P<0.05) lower that of TSB sham-vaccinated fish (FIG. 6).

TABLE 13 Cumulative mortality and relative percent survival (RPS) of vaccinated tilapia challenged with heterologous Streptococcus iniae isolates Challenge Isolate used for Dose Mortality RPSc Vaccine group challenge (CFU/fish) dpva (%) (%) Sham TSB ARS-98-60 4.8 × 107 60 80 — ISNO ARS-98-60 4.8 × 107 60 0 100 Sham TSB IF6-F3 1.1 × 108 60 100 — ISNO IF6-F3 1.1 × 108 60 0 100 Sham TSB 21101F3CB 1.9 × 107 60 90 — ISNO 21101F3CB 1.9 × 107 60 20  78 Sham TSB 21102F1K 4.8 × 107 60 100 — ISNO 21102F1K 4.8 × 107 60 10  90 Sham TSB 32405F1K 3.6 × 107 60 100 — ISNO 32405F1K 3.6 × 107 60 0 100 adays post vaccination; bintraperitoneal injection; crelative percent survival

Example 14

Indirect enzyme-linked immunosorbent assays (ELISA) were used to determine antibody titers using a previously described method (Shoemaker et al., J. Fish Dis., Volume 33, 537-544, 2010) with slight modifications. Briefly, 96-well ELISA plates were coated for about 1 hour at about 25 degrees C. with approximately 100 μl of S. iniae (ARS-98-60) antigen in carbonate buffer (CB), which was obtained from sonication and size-exclusion chromatography of S. iniae using approximately a 1:10 dilution in CB of the initial fraction representing the highest molecular weight fraction used. Plates were washed about three times with phosphate-buffered saline containing approximately 0.05% Tween-20 (PBS-T) and then blocked with approximately 3% bovine serum albumin in CB for about 1 hour. Following blocking, plates were washed about three times with PBS-T. Tilapia serum from five sham-vaccinated fish and five Streptococcus iniae vaccinated fish at different time points (each serum was tested in triplicate) was then added to the plate at about a 1:20 dilution in PBS-T. Serum was incubated for about 30 minutes followed by washing three times with PBS-T. Monoclonal anti-tilapia immunoglobulin (Shoemaker et al. 2010, supra) was diluted 1:1000 in PBS-T and then approximately added 100 μL per well was added to all wells for about 30 minutes. Following washing three times in PBS-T, approximately 100 μl of Monoclonal sheep anti-mouse IgG peroxidase conjugate at approximately 1:5000 dilution in PBS-T was added and incubated for about 15 minutes. Plates were then washed three times with PBS-T. Approximately 100 μl substrate tetramethylbenzidine (Pierce, Rockford, Ill.) was added. After about 15 minutes, the reaction was terminated by adding approximately 50 μl of approximately 3M H2SO4 to each well and the absorbance was read at approximately 450 nm using a BioRad 680 microplate reader (BioRad, Hercules, Calif.). Serum of S. iniae-infected fish post 28 days vaccination was used as a positive control and PBS was used as a negative control and both were included on each plate as assay controls.

ELISA results revealed that sham-vaccinated fish had absorbance readings similar to that of the negative control PBS at different time points. In ISNO vaccinated fish, the highest antibody titer was at about 14 days post vaccination, followed by a decline at about 28 days post vaccination and a further declines at about 60, 90 and 180 days post vaccination. At about 14 days post vaccination (pre-challenge), ISNO vaccinated tilapia produced significantly (P<0.001) higher antibody titer than TSB sham vaccinated tilapia (FIG. 7). At about 28 days post vaccination, antibody titer of ISNO vaccination vaccinated tilapia was lower than at about 14 days post vaccination. However, ISNO vaccinated tilapia still produced significantly (P 0.001) higher antibody titers than TSB sham vaccinated tilapia at about 28 days post vaccinated (FIG. 7). Antibody titers of ISNO vaccinated fish at about 60, 90, and 180 days post vaccination were all lower than that at about 14 and 28 days post vaccination. The antibody titer was not significantly different (P>0.05) between ISNO vaccinated fish and TSB sham vaccinated fish at about both 60 and 180 days post vaccination (FIG. 7).

Example 15

To develop vaccines using a novobiocin-like antibiotic, Streptococcus agalactiae was attenuated with a novobiocin-like chemical, coumermycin A1. Eight Streptococcus agalactiae isolates obtained from different fish species exhibiting clinical streptococcal disease and from different geographical regions were used for the induction of coumermycin resistance (Table 14). The archived isolates were recovered from frozen stocks (2 mL aliquots stored at −80° C.) and grown in tryptic soy broth (TSB) (Fisher Scientific, Pittsburgh, Pa.) for about 24 h at approximately 28° C. Coumermycin A1 was purchased from Promega (Madison, Wis.). All strains were cultured in tryptic soy broth (TSB) containing different concentrations of coumermycin for about 24 to about 48 h at approximately 28° C. The initial concentration of coumermycin that allowed overnight growth of Streptococcus agalactiae was approximately 1 ng/ml. Approximately 100 of that overnight culture was added into approximately 1 ml of tryptic soy broth containing 2 ng/ml of coumermycin. If the cells were able to grow in tryptic soy broth containing 2 ng/ml of coumermycin, approximately 10 μl of the overnight culture containing coumermycin at concentration of 2 ng/ml was then added into approximately 1 ml of tryptic soy broth containing 4 ng/ml of coumermycin. However, if the cells from the overnight culture at concentration of 1 ng/ml of coumermycin were unable to grow in tryptic soy broth containing 2 ng/ml of coumermycin, then approximately 10 μl of the overnight culture containing coumermycin at concentration of 1 ng/ml was added into approximately 1 ml of tryptic soy broth containing coumermycin equal to or higher than 1 ng/ml but less than 2 ng/ml. This process was repeated again and again until the cells were able to grow in culture media containing coumermycin at concentration of approximately 5000 ng/ml. After about 20 passages of Streptococcus agalactiae in TSB culture media containing same or higher concentration of coumermycin, all nine Streptococcus agalactiae strains were able grow in TSB containing approximately 5 μg/ml of coumermycin.

TABLE 14 Streptococcus agalactiae isolates used in this study Year Isolate designation isolated Location Species of fish Sag2/BZTN039HK 2003 Brazil Oreochromis niloticus Sag3/1SBHK 2002 Kuwait Dicentrarchus labrax Sag-4/DM 2001 Kuwait Tursiops truncatus Sag-5/BZTN031 2003 Brazil Oreochromis niloticus Sag-7/7BREID 2007 Idaho, USA Oreochromis spp. Sag-8/H90503 2005 Louisiana, USA Oreochromis spp. Sag-9/h05108A 2005 Louisiana, USA Morone saxatilis x M. chrysops Sag-10/F2BRFS 2007 Idaho, USA Oreochromis spp. Sag-12/2BRE 2007 Ecuador Oreochromis spp.

The nine parent and novobiocin-resistant Streptococcus agalactiae strains were then grown on 5% sheep blood agar plates (Thermo Fisher Scientific Remel Products, Lenexa, Kans.) for bacterial identification. Bacteria isolates were identified by gas chromatography analysis of fatty acid methyl ester using MIDI microbial identification system (MIDI, Newark, Del.) according to established procedures (Shoemaker et al. 2005. J Aqua Animal Health Volume 17, 267-274). Gas chromatography analysis of fatty acid methyl ester using MIDI microbial identification system confirmed that the parent and coumermycin-resistant isolates were Streptococcus agalactiae.

When parent Streptococcus agalactiae Sag3 isolate and coumermycin-resistant Streptococcus agalactiae Sag3C were plated onto 5% sheep blood agar plates, parent Streptococcus agalactiae Sag3 appeared to grow much faster than the coumermycin-resistant mutant Streptococcus agalactiae Sag3C (FIG. 8).

Example 16

The virulence of coumermycin-resistant Streptococcus agalactiae isolates were compared to their parent isolates. All parent and coumermycin-resistant Streptococcus agalactiae isolates were cultured overnight in tryptic soy broth (TSB) at approximately 28° C. An optical density (OD) of approximately 1.0 of the bacterial cultures was measured at approximately 540 nm using Thermospectronic spectrophotomer (Fisher Scientific, Pittsburgh, Pa.). Serial dilutions (in triplicates) of each isolate were prepared in TSB and approximately 100 μL of serially diluted Streptococcus agalactiae were plated onto TSA plates. After about 18 h incubation at approximately 28° C., the average number of CFU/mL was calculated for all isolates. Approximately 3.6×107 CFU/fish of each parent and coumermycin-resistant isolate was exposed to Nile tilapia, with a mean weight of about 20 grams, through intraperitoneal injection. All fish used in this study were male tilapia from the USDA ARS Aquatic Animal Health Research facility located at Auburn, Ala. Fish were acclimated in flow-through 57-L aquaria supplied with approximately 0.5 L h−1 dechlorinated water for about 10 days prior to experiments. A 12:12 h light:dark period of was maintained, and supplemental aeration was supplied by an air stone. Fish were fed approximately 3% body weight daily with commercial dry fish food. During the experiment, the mean dissolved oxygen was approximately 5.6 mg L-1, temperature was approximately 26° C., pH was about 7.1 and hardness was approximately 100 mg L-1. Mortalities were recorded for 14 days post exposure to Streptococcus agalactiae. Virulence data of both parent and coumermycin-resistant isolates of Streptococcus agalactiae are shown in Table 15.

When coumermycin-resistant Streptococcus agalactiae isolates were intraperitoneally injected to Nile tilapia, all nine isolates caused no mortality. However, when injected at similar dose, their respective parent isolates caused 100, 70, 80, 90, 80, 70, 100, 100, and 20% mortality, respectively (Table 15). The most virulent parent Streptococcus agalactiae isolates were Sag2, Sag9, and Sag 10, which killed 100% of Nile tilapia at the dose of approximately 3.6×107 CPU per fish (Table 15).

TABLE 15 Virulence of parent and coumermycin-resistant isolates of Streptococcus agalactiae to Nile tilapia by intraperitoneal injection Isolate name Mortality (%) Sag2-Ca 0 Sag2-Pb 100 Sag3-C 0 Sag3-P 70 Sag4-C 0 Sag4-P 80 Sag5-C 0 Sag5-P 90 Sag7-C 0 Sag7-P 80 Sag8-C 0 Sag8-P 70 Sag9-C 0 Sag9-P 100 Sag10-C 0 Sag10-P 100 Sag12-C 0 Sag12-P 20 aC stands for coumermycin-resistant isolate; bP stands for parent isolate.

Example 17

Nile tilapia were vaccinated with coumermycin-resistant Streptococcus agalactiae followed with a challenge by the virulent parent isolate. Attenuated coumermycin-resistant Streptococcus agalactiae vaccines were cultured in TSB at approximately 28° C. at about 125 rpm overnight before vaccination. Fish were vaccinated by intraperitoneal injection at dose of approximately 3.6×107 CFU per fish in a total volume of approximately 100 μl for each vaccine using ten fish per vaccine. As sham-vaccination controls, approximately 100 μl of TSB were injected into ten fish total. At about 21 days post vaccination (dpv), fish were challenged by parent isolate of Streptococcus agalactiae through intraperitoneal injection. Mortalities were recorded for about 14 days post challenge. Results of Streptococcus agalactiae challenge were presented as relative percent survival (RPS).

When coumermycin-resistant Streptococcus agalactiae Sag3C(NRRL B-50460)-vaccinated fish were challenged by its virulent parent isolate Streptococcus agalactiae Sag3P at approximately 21 dpv, relative percent survival of vaccinated fish was 100% (Table 16 and FIG. 9). However, when other coumermycin-resistant Streptococcus agalactiae mutant vaccinated fish were challenged by its virulent parent isolate, RPS value at approximately 21 dpv was all below approximately 10% (Table 16).

TABLE 16 Cumulative mortality and relative percent survival (RPS) of vaccinated tilapia challenged with virulent parent isolates Vaccination Isolate Challenge dose used for Dose Mortality RPSb Vaccine group (CFU/fish) challenge (CFU/fish) d.p.v.a (%) (%) Sham TSB — Sag2-Pd 3.6 × 107 21 100 — Sag2-Cc 3.6 × 107 Sag2-P 3.6 × 107 21 90 10  Sham TSB — Sag3-P 3.6 × 107 21 80 — Sag3-C 3.6 × 107 Sag3-P 3.6 × 107 21 0 100  Sham TSB — Sag4-P 3.6 × 107 21 40 — Sag4-C 3.6 × 107 Sag4-P 3.6 × 107 21 50 0 Sham TSB — Sag5-P 3.6 × 107 21 100 — Sag5-C 3.6 × 107 Sag5-P 3.6 × 107 21 100 0 Sham TSB — Sag7-P 3.6 × 107 21 80 — Sag7-C 3.6 × 107 Sag7-P 3.6 × 107 21 100 0 Sham TSB — Sag8-P 3.6 × 107 21 40 — Sag8-C 3.6 × 107 Sag8-P 3.6 × 107 21 60 0 Sham TSB — Sag9-P 3.6 × 107 21 100 — Sag9-C 3.6 × 107 Sag9-P 3.6 × 107 21 100 0 Sham TSB — Sag10-P 3.6 × 107 21 100 — Sag10-C 3.6 × 107 Sag10-P 3.6 × 107 21 100 0 Sham TSB — Sag12-P 3.6 × 107 21 20 — Sag12-C 3.6 × 107 Sag12-P 3.6 × 107 21 60 0 adays post vaccination; brelative percent survival; ccoumermycin-resistant isolate; dvirulent parent isolate

Example 18

The efficacy of Streptococcus agalactiae Sag3C against homologous Streptococcus agalactiae challenge was tested in Nile tilapia. Both parent and coumermycin-resistant mutant Streptococcus agalactiae Sag3C were cultured in TSB at approximately 28° C. at about 125 rpm overnight before vaccination or challenge.

Vaccination of Streptococcus agalactiae Sag3C was performed at vaccination dose of approximately 3.6×107 CFU in a total volume of approximately 0.1 ml per fish through intraperitoneal injection. Sham vaccination was performed by injecting approximately 0.1 ml of tryptic soy broth to each fish. At about 14 and 60 dpv, ten fish from each vaccination group (sham- or Streptococcus agalactiae Sag3C-vaccinated) at each time point were challenged by its parent isolate Streptococcus agalactiae Sag3P (homologous isolate) at dose of approximately 3.6×107 CFU per fish through intraperitoneal injection. Mortalities were recorded for about 14 days post challenge. Results of Streptococcus Streptococcus agalactiae challenge were presented as RPS.

At about 14 dpv, when TSB sham-vaccinated fish were challenged by its virulent parent strain Streptococcus agalactiae Sag3P, approximately 60% fish died (Table 17). However, when Streptococcus agalactiae Sag3C vaccinated fish were challenged by its virulent parent strain Streptococcus agalactiae Sag3P, no fish died (Table 17). The relative percent survival of Streptococcus agalactiae Sag3 C-vaccinated fish at about 14 dpv was 100% (Table 17). At about 60 dpv, when TSB sham-vaccinated fish were challenged by virulent strain Streptococcus agalactiae Sag3P, approximately 50% fish died (Table 17). However, when Streptococcus agalactiae Sag3C vaccinated fish were challenged by its virulent parent strain Streptococcus agalactiae Sag3P, only about 10% fish died (Table 17). The relative percent survival of vaccinated fish at about 60 dpv was approximately 80% (Table 17).

When fish were challenged by virulent parent strain Streptococcus agalactiae Sag3P, cumulative mortalities of virulent parent strain Streptococcus agalactiae Sag3C-vaccinated fish at different time points were significantly (P<0.05) lower that of TSB sham-vaccinated fish (FIG. 9).

TABLE 17 Cumulative mortality and relative percent survival (RPS) of vaccinated Nile tilapia challenged with virulent Streptococcus agalactiae Vaccination Challenge dose Dose Mortality RPSc Vaccine group (CFU/fish) (CFU/fish) d.p.v.a (%) (%) Sham TSB — 3.6 × 107 14 60 — Sag3C 3.6 × 107 3.6 × 107 14 0 100 Sham TSB — 3.6 × 107 60 50 — Sag3C 3.6 × 107 3.6 × 107 60 10  80 adays post vaccination; bintraperitoneal injection; crelative percent survival

Example 19

To develop vaccines using a novobiocin-like antibiotic, Edwardsiella tarda was attenuated with a novobiocin-like chemical, coumermycin A1. Eight Edwardsiella tarda isolates obtained from different fish species exhibiting clinical enteric septicemia collected from different geographical regions were used for the induction of coumermycin resistance (Table 18). The archived isolates were recovered from frozen stocks (2 mL aliquots stored at −80° C.) and grown in tryptic soy broth (TSB) (Fisher Scientific, Pittsburgh, Pa.) for about 24 h at approximately 28° C. Coumermycin A1 was purchased from Promega (Madison, Wis.). All strains were cultured in tryptic soy broth (TSB) containing different concentrations of coumermycin for about 24 to about 48 h at approximately 28° C. The initial concentration of coumermycin that allowed overnight growth of Edwardsiella tarda was approximately 312.5 ng/ml. Approximately 10 μl of that overnight culture was added into approximately 1 ml of tryptic soy broth containing 625 ng/ml of coumermycin. If the cells were able to grow in tryptic soy broth containing 625 ng/ml of coumermycin, approximately 10 μl of the overnight culture containing coumermycin at concentration of 625 ng/ml was then added into approximately 1 ml of tryptic soy broth containing 1250 ng/ml of coumermycin. However, if the cells from the overnight culture at concentration of 312.5 ng/ml of coumermycin were unable to grow in tryptic soy broth containing 625 ng/ml of coumermycin, then approximately 10 μl of the overnight culture containing coumermycin at concentration of 1 ng/ml was added into approximately 1 ml of tryptic soy broth containing coumermycin equal to or higher than 312.5 ng/ml but less than 625 ng/ml. This process was repeated again and again until the cells were able to grow in culture media containing coumermycin at concentration of approximately 640 μg/ml. After about 20 passages of Edwardsiella tarda in TSB culture media containing same or higher concentration of coumermycin, all eight Edwardsiella tarda strains were able grow in TSB containing approximately 640 μg/ml of coumermycin.

The eight parent and coumermycin-resistant Edwardsiella tarda strains were then grown on 5% sheep blood agar plates (Thermo Fisher Scientific Remel Products, Lenexa, Kans.) for bacterial identification. Bacteria isolates were identified by gas chromatography analysis of fatty acid methyl ester using MIDI microbial identification system (MIDI, Newark, Del.) according to established procedures (Shoemaker et al. 2005. J Aqua Animal Health Volume 17, 267-274). Gas chromatography analysis of fatty acid methyl ester using MIDI microbial identification system confirmed that parent and coumermycin-resistant mutants were all Edwardsiella tarda isolates.

When parent Edwardsiella tarda Eta9P or Eta11P isolate and coumermycin-resistant Edwardsiella tarda Eta9C or Eta11C were plated onto 5% sheep blood agar plates, parents and the coumermycin-resistant mutants of Edwardsiella tarda appeared to have the same growth rate (FIG. 10).

TABLE 18 Edwardsiella tarda isolates used in this study Year Isolate designation isolated Location Species of fish Eta1/FL6-60 2003 Florida, USA Ictalurus punctatus Eta2/RET04 2003 Florida, USA Ictalurus punctatus Eta4/AU9824 1998 Alabama, USA Ictalurus punctatus Eta7/CFBRAU 1998 Alabama, USA Ictalurus punctatus Eta8/TNBRAU 2005 Alabama, USA Oreochromis spp. Eta9/ALHSBK03 2003 Alabama, USA Morone saxatilis x M. chrysops Eta10/AU97052 1997 Alabama, USA Ictalurus punctatus Eta11/AL9368B 1993 Alabama, USA Ictalurus punctatus

Example 20

The virulence of coumermycin-resistant Edwardsiella tarda mutants were compared to their parent isolates. All parent and coumermycin-resistant Edwardsiella tarda isolates were cultured overnight in tryptic soy broth (TSB) at approximately 28° C. An optical density (OD) of about 1.0 of the bacterial cultures was measured at approximately 540 nm using Thermospectronic spectrophotomer (Fisher Scientific, Pittsburgh, Pa.). Serial dilutions (in triplicates) of each isolate were prepared in TSB and approximately 100 μL of serially diluted Edwardsiella tarda were plated onto TSA plates. After about 24 h incubation at approximately 28° C., the average number of CFU/mL was calculated for all isolates. Approximately 1×108 CFU/fish of each parent and coumermycin-resistant isolate was exposed to Nile tilapia having a mean weight of approximately 20 grams through intraperitoneal injection. All fish used in this study were male tilapia from the USDA ARS Aquatic Animal Health Research facility located at Auburn, Ala. Fish were acclimated in flow-through 57-L aquaria supplied with approximately 0.5 L h−1 dechlorinated water for about 10 days prior to experiments. A 12:12 h light:dark period of was maintained, and supplemental aeration was supplied by an air stone. Fish were fed approximately 3% body weight daily with commercial dry fish food. During the experiment, the mean dissolved oxygen was approximately 5.6 mg L-1, temperature was approximately 26° C., pH was about 7.1 and hardness was approximately 100 mg L-1. Mortalities were recorded for about 14 days post exposure to Edwardsiella tarda. Virulence data of both parent and coumermycin-resistant isolates of Edwardsiella tarda are shown in Table 19.

When coumermycin-resistant mutants of Edwardsiella tarda were intraperitoneal injected to Nile tilapia, five mutants (Eta2-C, Eta4-C, Eta7-C, Eta9-C, and Eta11-C) caused no mortality. However, when injected at similar dose, their respective parent isolates caused approximately 10, 40, 80, and 10% mortality, respectively (Table 19).

TABLE 19 Virulence of parent and coumermycin-resistant isolates of Edwardsiella tarda to Nile tilapia by intraperitoneal injection Isolate name Mortality (%) Eta1-Ca 20 Eta1-Pb 60 Eta2-C 0 Eta2-P 10 Eta4-C 0 Eta4-P 40 Eta7-C 0 Eta7-P 0 Eta8-C 20 Eta8-P 30 Eta9-C 0 Eta9-P 80 Eta10-C 30 Eta10-P 70 Eta11-C 0 Eta11-P 10 aC stands for coumermycin-resistant isolate; bP stands for parent isolate.

Example 21

This example shows the safety of the coumermycin-resistant mutants of E. tarda in channel catfish. The five coumermycin-resistant mutants Edwardsiella tarda were cultured overnight in tryptic soy broth (TSB) at approximately 28° C. An optical density (OD) of about 1.0 of the bacterial cultures was measured at approximately 540 nm using Thermospectronic spectrophotomer (Fisher Scientific, Pittsburgh, Pa.). Serial dilutions (in triplicates) of each isolate were prepared in TSB and approximately 100 μL of serially diluted Edwardsiella tarda were plated onto TSA plates. After about 24 h incubation at approximately 28° C., the average number of CFU/mL was calculated for all isolates. Approximately 1×108 CFU/fish of each parent and coumermycin-resistant isolate was exposed to channel catfish having a mean weight of approximately 25 grams through intraperitoneal injection. All fish used in this study were channel catfish from the USDA ARS Aquatic Animal Health Research facility located at Auburn, Ala. Fish were acclimated in flow-through 57-L aquaria supplied with approximately 0.5 L h−1 dechlorinated water for about 10 days prior to experiments. A 12:12 h light:dark period of was maintained, and supplemental aeration was supplied by an air stone. Fish were fed approximately 3% body weight daily with commercial dry fish food. During the experiment, the mean dissolved oxygen was approximately 5.6 mg L-1, temperature was approximately 26° C., pH was about 7.1 and hardness was approximately 100 mg L-1. Mortalities were recorded for 14 days post exposure to Edwardsiella tarda. Virulence data of the five coumermycin-resistant mutants of Edwardsiella tarda to channel catfish are shown in Table 20.

When coumermycin-resistant mutants of Edwardsiella tarda were intraperitoneal injected to channel catfish, three mutants (Eta7-C, Eta9-C, and Eta11-C) caused no mortality. However, when injected at similar dose, Eta2C and Eta4C killed approximately 15 and 100% channel catfish, respectively (Table 20).

TABLE 20 Virulence of the five coumermycin-resistant mutants of Edwardsiella tarda to channel catfish by intraperitoneal injection Isolate name Mortality (%) Eta2-Ca 15 Eta4-C 100 Eta7-C 0 Eta9-C 0 Eta11-C 0 aC stands for coumermycin-resistant isolate;

Example 22

To study the efficacy of the three coumermycin-resistant E. tarda mutants as vaccine candidates, channel catfish were vaccinated with the three coumermycin-resistant mutants (Eta7-C, Eta9-C, and Eta11-C) of Edwardsiella tarda through intraperitoneal injection and then challenged with virulent isolates of Edwardsiella tarda. Attenuated coumermycin-resistant mutants of Edwardsiella tarda were cultured in TSB at approximately 28° C. at about 125 rpm overnight before vaccination. Fish were vaccinated by intraperitoneal injection at dose of approximately 1×108 CFU per fish in a total volume of approximately 100 μl for each vaccine using ten fish per vaccine. As sham-vaccination controls, approximately 100 μl of TSB were injected into ten fish. At about 14 days post vaccination (dpv), fish were challenged by two virulent isolates of Edwardsiella tarda through intraperitoneal injection. Mortalities were recorded for about 14 days post challenge. Results of Edwardsiella tarda challenge were presented as relative percent survival (RPS).

At about 14 dpv, when three coumemnycin-resistant mutants (Eta7-C, Eta9-C, and Eta11-C) of Edwardsiella tarda-vaccinated fish were challenged by virulent isolate of Edwardsiella tarda LSU, relative percent survival of vaccinated fish was 100% (Table 21). At about 14 dpv, when coumermycin-resistant mutants of Edwardsiella tarda-vaccinated fish were challenged by virulent isolate of Edwardsiella tarda Eta9P, relative percent survival of coumermycin-resistant E. tarda Eta7C, E. tarda Eta9C (NRRL B-50468), and Eta11C (NRRL B-50467)-vaccinated fish were approximately 56, 78 and 100%, respectively (Table 21).

TABLE 21 Cumulative mortality and relative percent survival (RPS) of vaccinated channel catfish challenged with virulent isolates of Edwardsiella tarda Vaccination Isolate Challenge dose used for Dose Mortality RPSb Vaccine group (CFU/fish) challenge (CFU/fish) d.p.v.a (%) (%) Sham TSB — Eta-LSUd 5.7 × 106 14 70 — Eta7-Cc 1 × 108 Eta-LSU 5.7 × 106 14 0 100 Eta9-C 1 × 108 Eta-LSU 5.7 × 106 14 0 100 Eta11-C 1 × 108 Eta-LSU 5.7 × 106 14 0 100 Sham TSB — Eta-9Pd 2.3 × 106 14 90 — Eta7-Cc 1 × 108 Eta-9P 2.3 × 106 14 40  56 Eta9-C 1 × 108 Eta-9P 2.3 × 106 14 20  78 Eta11-C 1 × 108 Eta-9P 2.3 × 106 14 0 100 adays post vaccination; brelative percent survival; ccoumermycin-resistant isolate; dvirulent parent isolate

Example 23

To develop vaccines using both novobiocin-resistance and rifampicin-resistance strategy, a virulent strain of Aeromonas hydrophila AL#1 strain (designated AL09-72), isolated from diseased channel catfish from West Alabama during a disease outbreak in 2009, was used for the induction of novobiocin and rifampicin resistance. Initial cultures of the AL09-72 strain were grown in tryptic soy broth (TSB) containing no antibiotics at approximately 28 degrees C. for about 18-24 hours. Novobiocin sodium salt was purchased form Promega (Madison, Wis.). Rifampicin was purchased from Sigma (St. Louis, Mo.). The virulent strain of Aeromonas hydrophila strain AL09-72 was then subjected to selection for resistance to both novobiocin and rifampicin. The initial concentration that allowed overnight growth of A. hydrophila AL09-72 (AL#1) was 10 μg/ml for novobiocin and 10 μg/ml for rifampicin. Approximately 10 μl of that overnight culture was then added into approximately 1 ml of tryptic soy broth containing 20 μg/ml of novobiocin and 20 μg/ml of rifampicin. If the cells were able to grow in tryptic soy broth containing 20 μg/ml of novobiocin and rifampicin, approximately 10 μl of the overnight culture containing novobiocin and rifampicin at concentration of 20 μg/ml was then added into approximately 1 ml of tryptic soy broth containing 40 μg/ml of novobiocin and 40 μg/ml of rifampicin. However, if the cells from the overnight culture containing 10 μg/ml of novobiocin and 10 μg/ml of rifampicin were unable to grow in tryptic soy broth containing 20 μg/ml of novobiocin and 20 μg/ml of rifampicin, then approximately 10 μl of the overnight culture containing 10 μg/ml of novobiocin and 10 μg/ml of rifampicin was added into approximately 1 ml of tryptic soy broth containing novobiocin and rifampicin equal to or higher than 10 μg/ml but less than 20 μg/ml. This process was repeated multiple times until the cells were able to grow in culture media containing approximately 1600 μg/ml of novobiocin and 1600 μg/ml of rifampicin. The rifampicin and novobiocin mutated avirulent strain produced from AL09-72 is designated Aeromonas hydrophila strain N+R−1 NRRL B-50369.

Following the protocol described above, two other virulent Aeromonas hydrophila isolates, also isolated from diseased fish in 2009 during the disease outbreak in West Alabama, designated AL09-71 (also called AL#4) and AL09-73 (also called AL#2) were mutated with both rifampicin and novobiocin to avirulent forms of their virulent parents. The novobiocin and rifampicin resistant Aeromonas hydrophila AL#4 strain is designated as N+R−4 (NRRL B-50419), and the novobiocin and rifampicin resistant Aeromonas hydrophila AL#2 is designated as N+R−2 (NRRL B-50418). The three avirulent strains have been cultured in tryptic soy broth containing approximately 1600 μg/ml of rifampicin and novobiocin for more than three passages. The three avirulent strains can survive and reproduce on a media containing approximately 1600 μg/ml rifampicin and approximately 1600 μg/ml novobiocin without negative effect.

Example 24

The growth and biochemical characteristics of Aeromonas hydrophila N+R−1 NRRL B-50369, N+R−4 NRRL B-50419, and N+R−2 NRRL B-50418 were determined by growing the avirulent and virulent parental strains on tryptic soy agar plates. The biochemical characteristics were determined using API-20E bacterial identification test strip (Biomerieux, Durham, N.C.). NRRL B-50369, NRRL B-50419, and NRRL B-50418 grew slower on tryptic soy agar plates compared to their virulent parental strains. Biochemical analysis using API-20E bacterial identification test strip (Biomerieux, Durham, N.C.) revealed that parent and the novobiocin and rifampicin-resistant mutants of Aeromonas hydrophila had the same biochemical profiles (Table 22). When parent Aeromonas hydrophila AL#1 and the novobiocin and rifampicin-resistant mutant Aeromonas hydrophila N+R−1 were plated on 5% sheep blood agar plates, the growth of Aeromonas hydrophila N+R−1 was slower than that of Aeromonas hydrophila AL#1 (FIG. 11). Similarly, when parent Aeromonas hydrophila AL#4 or AL#2 and the novobiocin and rifampicin-resistant mutant Aeromonas hydrophila N+R−4 or N+R−2 were plated on 5% sheep blood agar plates, the growth of the novobiocin and rifampicin-resistant mutant Aeromonas hydrophila N+R−4 or N+R−2 was slower than its respective parent Aeromonas hydrophila AL#4 or AL#2 (FIGS. 12 and 13).

TABLE 22 Results of the API-20E bacterial identification test strip for the A. hydrophila N + R − 1. Results Results Results (Positive or negative) (Positive or negative) (Positive or negative) Tests Reactions/Enzymes AL09-72 N + R − 1 AL09-71 N + R − 4 AL09-73 N + R − 2 ONPG B-galactosidase Positive Positive Positive Positive Positive Positive ADH Arginine dihydrolase Positive Positive Positive Positive Positive Positive LDC Lysine decarboxylase Negative Negative Negative Negative Negative Negative ODC Ornithine decarboxylase Negative Negative Negative Negative Negative negative CIT Citrate Utilization Positive Positive Positive Positive Positive Positive H2S H2S Production Negative Negative Negative Negative Negative Negative URE Urease Negative Negative Negative Negative Negative Negative TDA Tryptophane deaminase Negative Negative Negative Negative Negative Negative IND Indole production Positive Positive Positive Positive Positive Positive VP Acetoin Production Positive Positive Positive Positive Positive Positive GEL Gelatinase Positive Positive Positive Positive Positive Positive GLU Fermentation/Oxidation Positive Positive Positive Positive Positive Positive (Gluscose) MAN Fermentation/Oxidation Positive Positive Positive Positive Positive Positive (mannitol) INO Fermentation/Oxidation Positive Positive Positive Positive Positive Positive (inositol) SOR Fermentation/Oxidation Negative Negative Negative Negative Negative Negative (sorbitol) RHA Fermentation/oxidation Negative Negative Negative Negative Negative Negative (rhamnose) SAC Fermentation/oxidation Positive Positive Positive Positive Positive Positive (saccharrose) MEL Fermentation/oxidation Negative Negative Negative Negative Negative Negative (melibiose) AMY Fermentation/oxidation Negative Negative Negative Negative Negative Negative (amygdalin) ARA Fermentation/oxidation Positive Positive Positive Positive Positive Positive (arabinose) OX Cytochrome-oxidase Positive Positive Positive Positive Positive Positive N + R − 4, and N + R − 2 strains compared to the virulent parent strains AL09-72, AL09-71 and AL09-73.

Example 25

The virulence of the three novobiocin and rifampicin-resistant mutants of Aeromonas hydrophila was then compared to the virulence of their parental virulent strains by intraperitoneal injection (IP) of the strains in channel catfish. Both the parent and the novobiocin and rifampicin-resistant mutants of Aeromonas hydrophila were cultured overnight in tyrptic soy broth (TSB) at approximately 27 degrees C. All catfish (Industry pool strain, USDA, Catfish Genetics Research Unit, Stoneville, Miss.) for this study were raised at the USDA ARS Aquatic Animal Research facility located at Auburn, Ala. and naïve to Aeromonas hydrophila. Intraperitoneal injection was performed by injecting different colony forming units (CFU) (See Tables 23-25) of Aeronomas hydrophila in a total volume of approximately 0.1 ml into catfish. Mortalities were recorded for approximately 14 days post exposure to A. hydrophila.

At dose of approximately 4×105 CFU per catfish, the parent Aeromonas hydrophila AL#1 killed 70% catfish. However, at similar dose of approximately 4×105 CFU per catfish, the mutant Aeromonas hydrophila N+R−1 was safe to catfish (Table 23). At dose of approximately 1×105 CFU per fish, the parent Aeromonas hydrophila AL#1 killed 100% catfish. However, at similar dose of approximately 1×105 CFU per fish, the mutant Aeromonas hydrophila N+R−1 was safe to catfish, causing no mortality (Table 23).

At dose of approximately 2.5×105 CFU per catfish, the parent Aeromonas hydrophila AL#2 killed 100% catfish (Table 24). However, at similar dose of approximately 2.5×105 CFU per catfish, the mutant Aeromonas hydrophila N+R−2 was safe to catfish, causing no mortality (Table 24). At dose of approximately 6.25×104 CFU per fish, the parent Aeromonas hydrophila AL#2 killed 80% catfish. However, at similar dose of approximately 6.25×104 CFU per fish, the mutant Aeromonas hydrophila N+R−2 was safe to catfish, causing no mortality (Table 24).

At dose of approximately 3.8×105 CFU per catfish, the parent Aeromonas hydrophila AL#4 killed 80% catfish (Table 25). However, at similar dose of approximately 3.8×105 CFU per catfish, the mutant Aeromonas hydrophila N+R−4 was safe to catfish, causing no mortality (Table 25). At dose of 4.75×104 CFU per fish, the parent Aeromonas hydrophila ALM killed 70% catfish. However, at similar dose of approximately 4.75×104 CFU per fish, the mutant Aeromonas hydrophila N+R−4 was safe to catfish, causing no mortality (Table 25).

TABLE 23 Virulence of N + R-1 and AL09-72 to catfish by intraperitoneal injection Fish weight No. of Exposure Amount Mortality Treatment (g) fish method (CFU/fish) (%)a TSBb control 6.95 10 injection — 0 AL09-72 6.95 10 injection 4 × 105 70 AL09-72 6.95 10 injection 2 × 105 80 AL09-72 6.95 10 injection 1 × 105 100 AL09-72 6.95 10 injection 5 × 104 90 N + R-1 6.95 10 injection 4 × 105 0 N + R-1 6.95 10 injection 2 × 105 0 N + R-1 6.95 10 injection 1 × 105 0 N + R-1 6.95 10 injection 5 × 104 0 acumulative mortality was calculated at 14 days post treatment; btryptic soy broth

TABLE 24 Virulence of N + R-2 and AL09-73 to catfish by intraperitoneal injection Fish weight No. of Exposure Amount Mortality Treatment (g) fish method (CFU/fish) (%)a TSBb control 6.95 10 injection — 0 AL09-73 6.95 10 injection 2.50 × 105 100 AL09-73 6.95 10 injection 1.25 × 105 70 AL09-73 6.95 10 injection 6.25 × 104 80 AL09-73 6.95 10 injection 3.13 × 104 90 N + R-2 6.95 10 injection 2.50 × 105 0 N + R-2 6.95 10 injection 1.25 × 105 0 N + R-2 6.95 10 injection 6.25 × 104 0 N + R-2 6.95 10 injection 3.13 × 104 0 acumulative mortality was calculated at 14 days post treatment; btryptic soy broth

TABLE 25 Virulence of N + R-4 and AL09-71 to catfish by intraperitoneal injection Fish weight No. of Exposure Amount Mortality Treatment (g) fish method (CFU/fish) (%)a TSBb control 6.95 10 injection — 0 AL09-71 6.95 10 injection 3.80 × 105 80 AL09-71 6.95 10 injection 1.90 × 105 80 AL09-71 6.95 10 injection 9.50 × 104 80 AL09-71 6.95 10 injection 4.75 × 104 70 N + R-4 6.95 10 injection 3.80 × 105 0 N + R-4 6.95 10 injection 1.90 × 105 0 N + R-4 6.95 10 injection 9.50 × 104 0 N + R-4 6.95 10 injection 4.75 × 104 0 acumulative mortality was calculated at 14 days post treatment; btryptic soy broth

Example 26

Nile Tilapia were also injected intraperitoneally with the three vaccines to assess safety. The attenuated and wild-type Aeromonas hydrophila were cultured overnight in tryptic soy broth (TSB) at approximately 27 degrees C. All Nile tilapia used in this example were raised at the USDA ARS Aquatic Research facility located at Auburn, Ala. and naïve to Aeromonas hydrophila. Intraperitoneal injections were performed by injecting different concentrations (colony forming units or CFU) (See Tables 26-28) of Aeromonas hydrophila, either a virulent parent strain or an avirulent or attenuated strain, in a total volume of approximately 0.1 ml. Mortalities were recorded for about 14 days post injection. After 14 days the only mortality recorded was for fish injected with the virulent parent strains of Aeromonas hydrophila.

At dose of approximately 3.2×108 CFU per Nile tilapia, the parent Aeromonas hydrophila AL#1 killed 100% catfish. However, at similar dose of approximately 3.2×108 CFU per Nile tilapia, the mutant Aeromonas hydrophila N+R−1 was safe for Nile tilapia, causing no mortality (Table 26).

At dose of approximately 2×108 CFU per Nile tilapia, the parent Aeromonas hydrophila AL#2 killed 100% catfish. However, at similar dose of approximately 2×108 CFU per Nile tilapia, the mutant Aeromonas hydrophila N+R−2 was safe for Nile tilapia, causing no mortality (Table 27).

At dose of approximately 3×108 CFU per Nile tilapia, the parent Aeromonas hydrophila AL#4 killed 100% catfish. However, at similar dose of approximately 3×108 CFU per Nile tilapia, the novobiocin and rifampicin resistant mutant Aeromonas hydrophila N+R−4 was safe for Nile tilapia, causing no mortality (Table 28).

TABLE 26 Injection of N + R-1 and AL09-72 to Nile tilapia by intraperitoneal injection. Fish weight No. of Exposure Amount Mortality Treatment (g) fish method (CFU/fish) (%)a TSBb control 15 10 injection — 0 AL09-72 15 10 injection 3.2 × 108 100 AL09-72 15 10 injection 3.2 × 107 0 AL09-72 15 10 injection 3.2 × 106 0 AL09-72 15 10 injection   8 × 105 0 N + R-1 15 10 injection 3.2 × 108 0 N + R-1 15 10 injection 3.2 × 107 0 N + R-1 15 10 injection 3.2 × 106 0 N + R-1 15 10 injection   8 × 105 0 acumulative mortality was calculated at 14 days post treatment

TABLE 27 Injection of N + R-2 and AL09-73 to Nile tilapia by intraperitoneal injection. Fish weight No. of Exposure Amount Mortality Treatment (g) fish method (CFU/fish) (%)a TSBb control 15 10 injection — 0 AL09-73 15 10 injection 2 × 108 100 AL09-73 15 10 injection 2 × 107 78 AL09-73 15 10 injection 2 × 106 0 AL09-73 15 10 injection 2 × 105 0 N + R-2 15 10 injection 2 × 108 0 N + R-2 15 10 injection 2 × 107 0 N + R-2 15 10 injection 2 × 106 0 N + R-2 15 10 injection 2 × 105 0 acumulative mortality was calculated at 14 days post treatment btryptic soy broth

TABLE 28 Injection of N + R-4 and AL09-71 to Nile tilapia by intraperitoneal injection. Fish weight No. of Exposure Amount Mortality Treatment (g) fish method (CFU/fish) (%)a TSBb control 15 10 injection — 0 AL09-71 15 10 injection 3 × 108 90 AL09-71 15 10 injection 3 × 107 70 AL09-71 15 10 injection 3 × 106 0 AL09-71 15 10 injection 3 × 105 0 N + R-4 15 10 injection 3 × 108 0 N + R-4 15 10 injection 3 × 107 0 N + R-4 15 10 injection 3 × 106 0 N + R-4 15 10 injection 3 × 105 0 acumulative mortality was calculated at 14 days post treatment btryptic soy broth

Example 27

The efficacy of the three novobiocin and rifampicin-resistant mutants of Aeromonas hydrophila as vaccine candidates was evaluated in channel catfish. Channel catfish were vaccinated by a single IP injection with either of the three novel Aeromonas hydrophila (See tables 29-31 for CFU/fish). Control fish were injected with TSB as a sham-vaccination control. After about 14 days post vaccination, channel catfish were challenged by the virulent parent strains of the attenuated Aeromonas hydrophila used in the vaccines through IP injection. Mortalities were recorded for 14 days post challenge and results in Tables 29-31 were presented as relative percent survival (RPS).

When TSB sham vaccinated fish were challenged with the virulent parent strain AL09-72 of Aeromonas hydrophila, all fish died. However, the fish vaccinated with the attenuated strain of N+R−1 at concentrations of 4×105, 2×105, and 5×104 CFU/fish all lived post challenge. Fish vaccinated with N+R−1 at a concentration of 1×105 had an approximately 90% survival rate (Table 29). When catfish were challenged by virulent AL09-72, cumulative mortalities of N+R+1 vaccinated fish were significantly (P<0.05) lower than that of TSB sham-vaccinated fish (FIG. 14).

When TSB sham vaccinated fish were challenged with the virulent parent strain AL09-73 of Aeromonas hydrophila, approximately 90% fish died. However, the fish vaccinated with the attenuated strain of N+R−2 at concentrations of 2.5×105 and 1.25×105CFU/fish all lived post challenge. Fish vaccinated with N+R−2 at a concentration of 6.25×104 and 3.13×104 had an approximately 90% survival rate (Table 30). Relative survival of N+R−2 vaccinated fish at all vaccination doses were approximately 89% to approximately 100% (Table 30). When catfish were challenged by virulent AL09-73, cumulative mortalities of N+R+2 vaccinated fish were significantly (P<0.05) lower than that of TSB sham-vaccinated fish (FIG. 15).

When TSB sham vaccinated fish were challenged with the virulent parent strain AL09-71 of Aeromonas hydrophila, approximately 70% fish died. However, the fish vaccinated with the attenuated strain of N+R−4 at concentrations of 1.9×105, and 4.75×104 CFU/fish all lived post challenge (Table 31). Fish vaccinated with N+R−4 at a concentration of 3.8×105 and 9.5×104 had an approximately 90% and approximately 80% survival rate, respectively (Table 31). Relative percent survival of N+R−4 vaccinated fish at all vaccination doses was approximately 71% to approximately 100% (Table 20). When catfish were challenged by virulent AL09-71, cumulative mortalities of N+R+4 vaccinated fish were significantly lower (P<0.05) than TSB sham-vaccinated fish (FIG. 16).

TABLE 29 Cumulative mortality and relative percent survival (RPS) of IP vaccinated catfish challenged with AL09-72 virulent strain Fish Vaccination starting Challenge Mortal- Vaccine dose weight Dose ity RPSb group (CFU/fish) (g) (CFU/fish) d.p.v.a (%) (%) TSBc — 6.95 4 × 105 15 100 — control N + R − 1 4 × 105 6.95 4 × 105 15 0 100 N + R − 1 2 × 105 6.95 4 × 105 15 0 100 N + R − 1 1 × 105 6.95 4 × 105 15 10 90 N + R − 1 5 × 104 6.95 4 × 105 15 0 100 adays post vaccination; brelative percent survival; ctryptic soy broth

TABLE 30 Cumulative mortality and relative percent survival (RPS) of IP vaccinated catfish challenged with AL09-73 virulent strain Fish Vaccination starting Challenge Mortal- Vaccine dose weight Dose ity RPSb group (CFU/fish) (g) (CFU/fish) d.p.v.a (%) (%) TSBc — 6.95 3 × 104 15 90 — control N + R − 2 2.50 × 105 6.95 3 × 104 15 0 100 N + R − 2 1.25 × 105 6.95 3 × 104 15 0 100 N + R − 2 6.25 × 104 6.95 3 × 104 15 10 89 N + R − 2 3.13 × 104 6.95 3 × 104 15 10 89 adays post vaccination; brelative percent survival; ctryptic soy broth

TABLE 31 Cumulative mortality and relative percent survival (RPS) of IP vaccinated catfish challenged with AL09-71 virulent strain Fish Vaccination starting Challenge Mortal- Vaccine dose weight Dose ity RPSb group (CFU/fish) (g) (CFU/fish) d.p.v.a (%) (%) TSBc — 6.95 4.75 × 104 15 70 — control N + R − 4 3.80 × 105 6.95 4.75 × 104 15 10 86 N + R − 4 1.90 × 105 6.95 4.75 × 104 15 0 100 N + R − 4 9.50 × 104 6.95 4.75 × 104 15 20 71 N + R − 4 4.75 × 104 6.95 4.75 × 104 15 0 100 adays post vaccination; brelative percent survival; ctryptic soy broth

Example 28

Example 27 above is repeated with Nile tilapia with the exception that tilapia were challenged approximately 28 days post vaccination with the virulent parent strains of the attenuated vaccine strains. As in Example 27, mortalities were recorded for approximately 14 days post challenge. Results of experimental challenge were presented as relative percent survival (RPS).

The TSB sham vaccinated fish challenged with the virulent parent strain AL09-72 of Aeromonas hydrophila had a mortality of approximately 92 to approximately 100% (Table 32). However, the fish vaccinated with the attenuated strain of N+R−1 at concentrations of 1.4×108, and 1.4×107 CFU/fish had a mortality of approximately 15% and approximately 24% respectively (Table 32). When the vaccination dose was equal or lower than approximately 1.4×106 CFU/fish, RPS value was equal to or lower than approximately 30% (Table 32). When N+R−1 vaccinated Nile tilapia were challenged by virulent AL09-72, cumulative mortalities of vaccinated fish at vaccination doses of 1.4×107, and 1.4×108 CFU/fish were significantly (P<0.05) lower than that of TSB sham-vaccinated fish (FIG. 17).

The TSB sham vaccinated fish challenged with the virulent parent strain AL09-73 of Aeromonas hydrophila had a mortality of approximately 90%. However, the fish vaccinated with the attenuated strain of N+R−2 at concentrations of 1.2×106, 1.2×107, and 1.2×108 CPU/fish all lived post challenge (Table 33). When N+R−2 vaccinated Nile tilapia were challenged by virulent AL09-73, cumulative mortalities of vaccinated fish, at vaccination doses of 1.2×106, 1.2×107, and 1.2×108 CFU/fish, were significantly (P<0.05) lower than that of TSB sham-vaccinated fish (FIG. 18).

The TSB sham vaccinated fish challenged with the virulent parent strain AL09-71 of Aeromonas hydrophila had a mortality of approximately 90%. However, the fish vaccinated with the attenuated strain of N+R−4 all lived post challenge (Table 34). When N+R−4 vaccinated Nile tilapia were challenged by virulent AL09-71, cumulative mortalities of vaccinated fish, at vaccination doses of 1.3×106, 1.3×107, and 1.3×108 CFU/fish, were significantly (P<0.05) lower than that of TSB sham-vaccinated fish (FIG. 19).

TABLE 32 Cumulative mortality and relative percent survival (RPS) of IP vaccinated Nile tilapia challenged with AL09-72 virulent strain Fish Vaccination starting Challenge Mortal- Vaccine dose weight Dose ity RPSb group (CFU/fish) (g) (CFU/fish) d.p.v.a (%) (%) TSBc — 10 3.2 × 107 28 92 — control N + R − 1 1.4 × 108 10 3.2 × 107 28 15 84 N + R − 1 1.4 × 107 10 3.2 × 107 28 24 74 N + R − 1 1.4 × 107 10 3.2 × 107 28 64 30 N + R − 1 1.4 × 106 10 3.2 × 107 28 68 26 N + R − 1 1.4 × 105 10 3.2 × 107 28 80 13 N + R − 1 1.4 × 104 10 3.2 × 107 28 92 0 adays post vaccination; brelative percent survival; ctryptic soy broth

TABLE 33 Cumulative mortality and relative percent survival (RPS) of IP vaccinated Nile tilapia challenged with AL09-73 virulent strain Fish Vaccination starting Challenge Mortal- Vaccine dose weight Dose ity RPSb group (CFU/fish) (g) (CFU/fish) d.p.v.a (%) (%) TSBc — 15 1.2 × 107 28 90 — control N + R − 2 1.2 × 108 15 1.2 × 107 28 0 100 N + R − 2 1.2 × 107 15 1.2 × 107 28 0 100 N + R − 2 1.2 × 106 15 1.2 × 107 28 0 100 adays post vaccination; brelative percent survival; ctryptic soy broth

TABLE 34 Cumulative mortality and relative percent survival (RPS) of IP vaccinated Nile tilapia challenged with AL09-71 virulent strain Fish Vaccination starting Challenge Mortal- Vaccine dose weight Dose ity RPSb group (CFU/fish) (g) (CFU/fish) d.p.v.a (%) (%) TSBc — 15 1.3 × 107 28 90 — control N + R − 4 1.3 × 108 15 1.3 × 107 28 0 100 N + R − 4 1.3 × 107 15 1.3 × 107 28 0 100 N + R − 4 1.3 × 106 15 1.3 × 107 28 0 100 adays post vaccination; brelative percent survival; ctryptic soy broth

All publications and patents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.

The foregoing detailed description and certain representative embodiments and details of the invention have been presented for purposes of illustration and description of the invention. It is not intended to be exhaustive or to limit the invention to the precise forms disclosed. It will be apparent to practitioners skilled in the art that modifications and variations may be made therein without departing from the scope of the invention.

Claims

1-34. (canceled)

35. An isolated attenuated strain of Aeromonas hydrophila deposited with USDA ARS Patent Culture Collection, selected from the group consisting of accession number NRRL B-50369, accession number NRRL B-50418, accession number NRRL B-50419, and mixtures thereof.

36. A vaccine composition for protecting aquatic animals against infection by Aeromonas hydrophila comprising:

a. an immunologically effective amount of an isolated attenuated strain of Aeromonas hydrophila resistant to novobiocin or a novobiocin-like antibiotic and deposited with USDA ARS Patent Culture Collection, selected from the group consisting of accession number NRRL B-50369, accession number NRRL B-50418, accession number NRRL B-50419, and mixtures thereof; and
b. a carrier.

37. A method of protecting aquatic animals against infection by Aeromonas hydrophila comprising administering to said aquatic animals the isolated attenuated strain of Aeromonas hydrophila of claim 35.

38. A method of protecting aquatic animals against infection by Aeromonas hydrophila comprising administering to said aquatic animals the vaccine composition of claim 36.

Patent History
Publication number: 20140086955
Type: Application
Filed: Nov 29, 2013
Publication Date: Mar 27, 2014
Inventors: Yuping Wei Pridgeon (Auburn, AL), Phillip Harry Klesius (Auburn, AL)
Application Number: 14/093,120